

# Quarterly rpt on consolidated results for the financial period ended 30 Jun 2021

## IHH HEALTHCARE BERHAD

|   |                       |
|---|-----------------------|
| Financial Year End                              | 31 Dec 2021           |
| Quarter   | 2 Qtr                 |
| Quarterly report for the financial period ended | 30 Jun 2021           |
| The figures                                     | have not been audited |

### Attachments



[IHH Q2 2021 Quarterly Report.pdf](#)  
450.6 kB



[IHH Q2 2021 Press Release 26.08.2021.pdf](#)  
758.4 kB

Default Currency

Other Currency

Currency: Malaysian Ringgit (MYR)

### SUMMARY OF KEY FINANCIAL INFORMATION 30 Jun 2021

|   |   | INDIVIDUAL PERIOD            |                                      | CUMULATIVE PERIOD                  |                                     |
|---|---|------------------------------|--------------------------------------|------------------------------------|-------------------------------------|
|   |   | CURRENT YEAR QUARTER         | PRECEDING YEAR CORRESPONDING QUARTER | CURRENT YEAR TO DATE               | PRECEDING YEAR CORRESPONDING PERIOD |
|   |   | 30 Jun 2021                  | 30 Jun 2020                          | 30 Jun 2021                        | 30 Jun 2020                         |
|   |   | \$\$'000                     | \$\$'000                             | \$\$'000                           | \$\$'000                            |
| 1 | Revenue   | 4,270,271                    | 2,565,110                            | 8,216,051                          | 6,120,286                           |
| 2 | Profit/(loss) before tax  | 668,463                      | -232,032                             | 1,254,960                          | -489,389                            |
| 3 | Profit/(loss) for the period  | 546,084                      | -232,146                             | 978,971                            | -598,806                            |
| 4 | Profit/(loss) attributable to ordinary equity holders of the parent               | 483,306                      | -120,642                             | 858,927                            | -440,428                            |
| 5 | Basic earnings/(loss) per share (Subunit)   | 5.26                         | -1.64                                | 9.29                               | -5.54                               |
| 6 | Proposed/Declared dividend per share (Subunit)                                    | 0.00                         | 0.00                                 | 0.00                               | 0.00                                |
|   |   | AS AT END OF CURRENT QUARTER |                                      | AS AT PRECEDING FINANCIAL YEAR END |                                     |
| 7 | Net assets per share attributable to ordinary equity holders of the parent (\$\$) | 2.5300                       |                                      | 2.4800                             |                                     |

Definition of Subunit:

In a currency system, there is usually a main unit (base) and subunit that is a fraction amount of the main unit.  
Example for the subunit as follows:

| Country        | Base Unit | Subunit |
|----------------|-----------|---------|
| Malaysia       | Ringgit   | Sen     |
| United States  | Dollar    | Cent    |
| United Kingdom | Pound     | Pence   |

**Announcement Info**

|                         |                       |
|-------------------------|-----------------------|
| <b>Company Name</b>     | IHH HEALTHCARE BERHAD |
| <b>Stock Name</b>       | IHH                   |
| <b>Date Announced</b>   | 26 Aug 2021           |
| <b>Category</b>         | Financial Results     |
| <b>Reference Number</b> | FRA-26082021-00035    |



IHH HEALTHCARE BERHAD  
Registration No. 201001018208 (901914-V)  
(Incorporated in Malaysia)

INTERIM FINANCIAL REPORT  
30 JUNE 2021

**UNAUDITED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME FOR THE FINANCIAL PERIOD ENDED 30 JUNE 2021**

|   |      | 2nd quarter ended |                  |           | Financial period ended |                  |           |
|---|------|-------------------|------------------|-----------|------------------------|------------------|-----------|
|   | Note | 30 Jun 2021       | 30 Jun 2020      | Variance  | 30 Jun 2021            | 30 Jun 2020      | Variance  |
|   |      | RM'000            | RM'000           | %         | RM'000                 | RM'000           | %         |
| <b>Revenue</b>  | 1    | 4,270,271         | 2,565,110        | 66%       | 8,216,051              | 6,120,286        | 34%       |
| Other operating income  | 2    | 306,012           | 158,491          | 93%       | 401,201                | 264,087          | 52%       |
| Inventories and consumables   |      | (921,010)         | (561,235)        | -64%      | (1,739,242)            | (1,277,133)      | -36%      |
| Purchased and contracted services   |      | (364,415)         | (266,855)        | -37%      | (720,351)              | (634,063)        | -14%      |
| Staff costs   | 3    | (1,502,748)       | (1,239,125)      | -21%      | (2,944,227)            | (2,608,801)      | -13%      |
| Depreciation and impairment of property, plant and equipment                              | 4    | (382,340)         | (235,150)        | -63%      | (619,501)              | (473,986)        | -31%      |
| Depreciation of right-of-use ("ROU") assets   |      | (78,607)          | (90,235)         | 13%       | (155,153)              | (175,563)        | 12%       |
| Amortisation and impairment of intangible assets  |      | (11,747)          | (14,282)         | 18%       | (24,167)               | (31,286)         | 23%       |
| Operating lease expenses  |      | (20,172)          | (15,520)         | -30%      | (37,592)               | (31,417)         | -20%      |
| Other operating expenses  | 5    | (476,904)         | (370,485)        | -29%      | (920,450)              | (1,264,516)      | 27%       |
| Finance income  | 6    | 13,039            | 58,184           | -78%      | 188,949                | 130,916          | 44%       |
| Finance costs   | 6    | (172,715)         | (217,356)        | 21%       | (416,934)              | (505,990)        | 18%       |
| Share of profits of associates (net of tax)   | 7    | 10,930            | 1,011            | NM        | 18,331                 | 1,991            | NM        |
| Share of (losses)/profits of joint ventures (net of tax)                                  | 8    | (1,131)           | (4,585)          | 75%       | 8,045                  | (3,914)          | NM        |
| <b>Profit/(Loss) before tax</b>   |      | <b>668,463</b>    | <b>(232,032)</b> | <b>NM</b> | <b>1,254,960</b>       | <b>(489,389)</b> | <b>NM</b> |
| Income tax expense  | 9    | (122,379)         | (114)            |           | (275,989)              | (109,417)        | -152%     |
| <b>Profit/(Loss) for the period</b>   |      | <b>546,084</b>    | <b>(232,146)</b> | <b>NM</b> | <b>978,971</b>         | <b>(598,806)</b> | <b>NM</b> |
| <b>Other comprehensive income, net of tax</b>   |      |                   |                  |           |                        |                  |           |
| <b>Items that are or may be reclassified subsequently to profit or loss</b>               |      |                   |                  |           |                        |                  |           |
| Foreign currency translation differences from foreign operations                          | 10   | (106,647)         | 31,932           | NM        | (21,804)               | (91,582)         | 76%       |
| Realisation of FCTR <sup>1</sup> upon disposal/substantive liquidation of a joint venture |      | 22,148            | 434              | NM        | 22,148                 | 60,419           | -63%      |
| Hedge of net investments in foreign operations  | 10   | (5,523)           | 44,263           | -112%     | 39,270                 | (85,031)         | 146%      |
| Cash flow hedge   |      | 595               | (6,689)          | 109%      | 8,426                  | (9,108)          | 193%      |
| Cost of hedging reserve   |      | (1,483)           | (702)            | -111%     | 370                    | (75)             | NM        |
|   |      | (90,910)          | 69,238           | NM        | 48,410                 | (125,377)        | 139%      |
| <b>Items that will not be reclassified subsequently to profit or loss</b>                 |      |                   |                  |           |                        |                  |           |
| Remeasurement of defined benefit liabilities  |      | (986)             | (1,730)          | 43%       | 1,159                  | (4,573)          | 125%      |
| <b>Total comprehensive income for the period</b>  |      | <b>454,188</b>    | <b>(164,638)</b> | <b>NM</b> | <b>1,028,540</b>       | <b>(728,756)</b> | <b>NM</b> |
| <b>Profit/(Loss) attributable to:</b>   |      |                   |                  |           |                        |                  |           |
| Owners of the Company   |      | 483,306           | (120,642)        | NM        | 858,927                | (440,428)        | NM        |
| Non-controlling interests   |      | 62,778            | (111,504)        | 156%      | 120,044                | (158,378)        | 176%      |
| <b>Profit/(Loss) for the period</b>   |      | <b>546,084</b>    | <b>(232,146)</b> | <b>NM</b> | <b>978,971</b>         | <b>(598,806)</b> | <b>NM</b> |
| <b>Total comprehensive income attributable to:</b>  |      |                   |                  |           |                        |                  |           |
| Owners of the Company   |      | 437,218           | (34,891)         | NM        | 904,768                | (489,703)        | NM        |
| Non-controlling interests   |      | 16,970            | (129,747)        | 113%      | 123,772                | (239,053)        | 152%      |
| <b>Total comprehensive income for the period</b>  |      | <b>454,188</b>    | <b>(164,638)</b> | <b>NM</b> | <b>1,028,540</b>       | <b>(728,756)</b> | <b>NM</b> |
| <b>Earnings per share (sen)</b>   |      |                   |                  |           |                        |                  |           |
| Basic   |      | 5.26              | (1.64)           | NM        | 9.29                   | (5.54)           | NM        |
| Diluted   |      | 5.26              | (1.64)           | NM        | 9.29                   | (5.53)           | NM        |

NM: Not meaningful

Note:

1. Foreign currency translation reserve

**UNAUDITED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME FOR THE FINANCIAL PERIOD ENDED 30 JUNE 2021**

**SUPPLEMENTARY INFORMATION**

|   |      | 2nd quarter ended |                  |           | Financial period ended |                  |           |
|---|------|-------------------|------------------|-----------|------------------------|------------------|-----------|
|   | Note | 30 Jun 2021       | 30 Jun 2020      | Variance  | 30 Jun 2021            | 30 Jun 2020      | Variance  |
|   |      | RM'000            | RM'000           | %         | RM'000                 | RM'000           | %         |
| <b>Profit/(Loss) attributable to owners of the Company</b>                                |      | <b>483,306</b>    | <b>(120,642)</b> | <b>NM</b> | <b>858,927</b>         | <b>(440,428)</b> | <b>NM</b> |
| <b>Add back/(less): Exceptional items ("EI")</b>  |      |                   |                  |           |                        |                  |           |
| Remeasurement to fair value of interest in a joint venture <sup>i</sup>                   |      | (85,768)          | -                |           | (85,768)               | -                |           |
| Impairment loss on goodwill <sup>ii</sup>   | 5    | -                 | (1,330)          |           | -                      | 399,153          |           |
| Gain on disposal of a subsidiary <sup>iii</sup>   |      | -                 | -                |           | -                      | (13,188)         |           |
| Gain on disposal of a joint venture <sup>iv</sup>   |      | (139,053)         | -                |           | (139,053)              | -                |           |
| Realisation of FCTR upon disposal/substantive liquidation of a joint venture <sup>v</sup> | 5    | -                 | 434              |           | -                      | 60,419           |           |
| Provision for loan taken by a joint venture <sup>vi</sup>                                 |      | -                 | 1,279            |           | -                      | 2,441            |           |
| Impairment of assets <sup>vii</sup>   |      | 189,998           | -                |           | 189,998                | -                |           |
| Change in fair value of cross currency swaps <sup>viii</sup>                              | 6    | 910               | (43,252)         |           | (154,983)              | (96,216)         |           |
| Exchange loss on net borrowings <sup>ix</sup>   | 6    | 58,724            | 94,826           |           | 157,928                | 228,652          |           |
|   |      | 24,811            | 51,957           |           | (31,878)               | 581,261          |           |
| Less: Tax effects on EI   |      | (14,909)          | (11,459)         |           | (2,437)                | (26,347)         |           |
| Less: Non-controlling interests' share of EI  |      | (29,624)          | (4,011)          |           | (25,202)               | (9,290)          |           |
|   |      | (19,722)          | 36,487           |           | (59,517)               | 545,624          |           |
| <b>Profit/(Loss) attributable to owners of the Company, excluding EI<sup>x</sup></b>      |      | <b>463,584</b>    | <b>(84,155)</b>  | <b>NM</b> | <b>799,410</b>         | <b>105,196</b>   | <b>NM</b> |
| <b>Earnings per share, excluding EI<sup>†</sup> (sen)</b>                                 |      |                   |                  |           |                        |                  |           |
| Basic   |      | 5.03              | (1.22)           | NM        | 8.61                   | 0.68             | NM        |
| Diluted   |      | 5.03              | (1.22)           | NM        | 8.61                   | 0.68             | NM        |

NM: Not meaningful

Note:

"Acibadem Holdings" as referred to throughout this financial report includes the wholly-owned Integrated Healthcare Turkey Yatirimlari Limited Group, which owns approximately 90% interest in Acibadem Sağlık Yatirimlari Holding A.Ş. Group.

- Remeasurement to fair value of interests in DDRC SRL Diagnostics Private Limited ("DDRC SRL"), upon acquisition of controlling interest in DDRC SRL
- Impairment of goodwill over Ravindranath GE Medical Associates Pte Ltd (also known as "Global Hospitals")
- Disposal of 70% interest in Famicord Acibadem Kordon Kani Saglik Hizmetleri Anonim Sirketi
- Disposal of a joint venture – Apollo Gleneagles Hospital Ltd, net of realisation of FCTR of RM22.1 million loss
- Realisation of FCTR upon substantive liquidation of Khubchandani Hospital (a joint venture)
- Provision for proportionate share of amounts owed by Khubchandani Hospitals on its loans, that is unlikely to be repaid
- Impairment of assets of Gleneagles Chengdu Hospital (the Group's hospital that was operational in late 2019 whose ramp up was longer than expected and was hampered by the COVID-19 pandemic) and Andaman Alliance Healthcare Limited ("AAHL") (the Group's greenfield hospital project in Myanmar which has stalled)
- Fair value changes of cross-currency swaps which were entered to hedge a portion of Acibadem Holdings' foreign currency denominated borrowings
- Exchange differences arising from foreign currency denominated borrowings/payables net of foreign currency denominated cash/receivables, recognised by Acibadem Holdings (As at 30 June 2021, Euro/TL=10.3645)
- Exceptional items, net of tax and non-controlling interests

The unaudited Consolidated Statement of Profit or Loss and Other Comprehensive Income should be read in conjunction with the 2020 Audited Financial Statements and the accompanying explanatory notes attached to this financial report.

## EXPLANATORY NOTES TO THE STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

The Group's reported results were also impacted by the relative movements in Ringgit Malaysia ("RM") against the exchange rates of the countries that the Group operates in. The RM weakened against Singapore Dollars ("SGD") and strengthened against Turkish Lira ("TL") in the current quarter and period as compared to the corresponding period last year.

Refer to Section B1 for performance review of the Group's major operating segments.

1. QTD 2020 and YTD 2020 were low bases due to major lockdowns in various markets the Group operates in, including Singapore, Malaysia, India and Turkey as a result of COVID-19 pandemic. During this period, patients postponed non-urgent and non-essential treatments and visits to hospitals and healthcare facilities. Patient volumes picked up as the lockdowns gradually eased to varying extent since June 2020. In addition, the magnitude of COVID-19 related-services provided by the Group increased as the pandemic continues. These, together with contribution from DDRC SRL Diagnostics Private Limited ("DDRC SRL") which was consolidated as a subsidiary from 5 April 2021 and contribution from Prince Court Medical Centre ("PCMC") which was acquired on 1 September 2020, led to higher revenue recorded in QTD 2021 and YTD 2021.
2. Increase in QTD 2021 and YTD 2021 other operating income was mainly due to gain on disposal of Apollo Gleneagles Hospital Ltd (a joint venture) of RM139.1 million and remeasurement to fair value of interest in DDRC SRL of RM85.8 million. The increase was offset by lower government grant income recorded.
3. Increase in QTD 2021 and YTD 2021 staff costs was mainly due to a low base last year with lower doctors' salaries for certain groups of doctors whose salaries vary with revenue or services rendered. The hire of contract employees for COVID-19 related services rendered, as well as the consolidation of DDRC SRL's and PCMC's staff costs upon acquisition also contributed to the higher staff costs.
4. Increase in QTD 2021 and YTD 2021 depreciation and impairment of property, plant and equipment was due to impairment loss of RM146.8 million for Gleneagles Chengdu Hospital.
5. YTD 2020 other operating expenses included impairment of goodwill over Global Hospitals amounting to RM399.2 million and realisation of FCTR amounting to RM60.4 million loss upon the substantive liquidation of Khubchandani Hospital. Whereas YTD 2021 other operating expenses included the impairment of assets by Andaman Alliance Healthcare Limited ("AAHL") of RM43.2 million, as well as the consolidation of DDRC SRL's and PCMC's other operating expenses upon acquisition. As a result, the Group recorded lower other operating expenses for YTD 2021 as compared to YTD 2020. However, other operating expense increased in QTD 2021 due to the impairment of AAHL's assets being recognised in the current quarter.
6. Acibadem Holdings recognised exchange gain or loss arising from the translation of its non-TL denominated borrowings/payables net of its non-TL denominated cash/receivables as finance income or finance cost respectively. Acibadem Holdings manages its foreign exchange exposures by entering into cross-currency swaps ("CCS").

In QTD 2021, the Group recognised a higher net loss of RM59.6 million as compared to net loss of RM51.6 million in QTD 2020. In YTD 2021, the Group recognised a lower net loss of RM2.9 million as compared to net loss of RM132.4 million for YTD 2020.

Besides the CCS, the Group also recorded net fair value loss of RM0.8 million for QTD 2021 on other financial derivatives, mainly held by PLife REIT, as compared to a net gain of RM8.9 million for QTD 2020. Net fair value gain of RM9.6 million was recorded for YTD 2021, as compared to net loss of RM3.5 million for YTD 2020.

7. Higher share of profits of associates in QTD 2021 and YTD 2021 was mainly attributed to Gleneagles JPMC Sdn Bhd which became an associate of the Group since October 2020.
8. Higher share of profits of joint ventures in YTD 2021 was attributed to income from COVID-19 related services rendered by the joint ventures.
9. Refer to Section B5 for details on income tax expenses.
10. PLife REIT hedges its interest in the net assets of its Japanese operations. The effective portion of the hedge was recognised as a hedge of net investments in the statement of other comprehensive income, which offsets the foreign currency translation differences from the translation of the net assets of its Japanese operations. The Group's remaining foreign currency translation differences from foreign operations arise mainly from the translation of the net assets of its Singapore and Turkish operations.

Note:

Key average exchange rates used to translate the YTD results of overseas subsidiaries into RM:

|       | 30 Jun 2021 | 30 Jun 2020 |
|-------|-------------|-------------|
| 1 SGD | 3.0747      | 3.0384      |
| 1 TL  | 0.5220      | 0.6587      |

**UNAUDITED CONSOLIDATED STATEMENT OF FINANCIAL POSITION  
AS AT 30 JUNE 2021**

|                                    | Note | 30 Jun 2021<br>RM'000 | 31 Dec 2020<br>RM'000 |
|------------------------------------|------|-----------------------|-----------------------|
| <b>Assets</b>                      |      |                       |                       |
| Property, plant and equipment      |      | 11,357,880            | 11,569,497            |
| Right-of-use assets                |      | 6,487,738             | 6,612,132             |
| Investment properties              |      | 3,561,877             | 3,612,547             |
| Goodwill on consolidation          | 1    | 12,377,335            | 12,123,112            |
| Intangible assets                  | 1    | 2,081,751             | 1,990,429             |
| Interests in associates            |      | 143,235               | 142,869               |
| Interests in joint ventures        | 1    | 6,023                 | 122,765               |
| Other financial assets             |      | 64,925                | 63,891                |
| Trade and other receivables        |      | 124,512               | 127,329               |
| Tax recoverables                   | 2    | 270,039               | 287,697               |
| Derivative assets                  |      | 201,376               | 108,304               |
| Deferred tax assets                |      | 427,364               | 427,749               |
| <b>Total non-current assets</b>    |      | <b>37,104,055</b>     | <b>37,188,321</b>     |
| Development properties             |      | 80,606                | 90,083                |
| Inventories                        |      | 446,283               | 420,153               |
| Trade and other receivables        | 3    | 2,349,391             | 1,953,142             |
| Tax recoverables                   |      | 24,287                | 21,760                |
| Other financial assets             | 4    | 405,396               | 422,593               |
| Derivative assets                  |      | 70,623                | 33,410                |
| Cash and cash equivalents          |      | 4,054,635             | 4,187,806             |
|                                    |      | 7,431,221             | 7,128,947             |
| Assets classified as held for sale | 5    | 8,182                 | 216,992               |
| <b>Total current assets</b>        |      | <b>7,439,403</b>      | <b>7,345,939</b>      |
| <b>Total assets</b>                |      | <b>44,543,458</b>     | <b>44,534,260</b>     |

**UNAUDITED CONSOLIDATED STATEMENT OF FINANCIAL POSITION  
AS AT 30 JUNE 2021**

|  | Note | 30 Jun 2021<br>RM'000 | 31 Dec 2020<br>RM'000 |
|--|------|-----------------------|-----------------------|
| <b>Equity</b>  |      |                       |                       |
| Share capital  |      | 19,483,491            | 19,473,364            |
| Other reserves   |      | (2,002,278)           | (1,988,281)           |
| Retained earnings  |      | 4,719,086             | 4,254,736             |
| <b>Total equity attributable to owners of the Company</b>                    |      | <b>22,200,299</b>     | <b>21,739,819</b>     |
| Perpetual securities   |      | 2,156,915             | 2,158,061             |
| Non-controlling interests  |      | 3,073,427             | 3,137,489             |
| <b>Total equity</b>  |      | <b>27,430,641</b>     | <b>27,035,369</b>     |
| <b>Liabilities</b>   |      |                       |                       |
| Loans and borrowings   | 6    | 7,971,171             | 8,664,676             |
| Lease liabilities  |      | 1,631,321             | 1,704,084             |
| Employee benefits  |      | 129,303               | 117,678               |
| Trade and other payables   | 7    | 1,176,211             | 228,330               |
| Derivative liabilities   |      | 636                   | 800                   |
| Deferred tax liabilities   |      | 1,230,051             | 1,168,256             |
| <b>Total non-current liabilities</b>   |      | <b>12,138,693</b>     | <b>11,883,824</b>     |
| Bank overdrafts  |      | 37,322                | 22,401                |
| Loans and borrowings   | 6    | 998,889               | 996,384               |
| Lease liabilities  |      | 234,401               | 241,226               |
| Employee benefits  |      | 154,360               | 147,238               |
| Trade and other payables   | 7    | 3,245,283             | 3,891,883             |
| Derivative liabilities   |      | 17                    | 7,316                 |
| Tax payable  |      | 303,133               | 289,595               |
|  |      | 4,973,405             | 5,596,043             |
| Liabilities classified as held for sale                                      | 5    | 719                   | 19,024                |
| <b>Total current liabilities</b>   |      | <b>4,974,124</b>      | <b>5,615,067</b>      |
| <b>Total liabilities</b>   |      | <b>17,112,817</b>     | <b>17,498,891</b>     |
| <b>Total equity and liabilities</b>  |      | <b>44,543,458</b>     | <b>44,534,260</b>     |
| Net assets per share attributable to owners of the Company <sup>1</sup> (RM) |      | 2.53                  | 2.48                  |

Note:

1. Based on 8,779.1 million and 8,777.2 million shares issued as at 30 June 2021 and 31 December 2020 respectively.

## EXPLANATORY NOTES TO THE STATEMENT OF FINANCIAL POSITION

The Group's reported financial position was also impacted by the relative movements in Ringgit Malaysia ("RM") against the exchange rates of the countries that the Group operates in. The RM weakened against SGD and strengthened against TL as at 30 June 2021 as compared to 31 December 2020.

1. Goodwill and intangible assets increased due to acquisition of remaining 50% equity interest in a joint venture, DDRC SRL, on 5 April 2021.

As a result of the acquisition, DDRC SRL ceased to be a joint venture and became a subsidiary of the Group. This led to the decrease in interests in joint ventures.

2. Non-current tax recoverable decreased due to income tax refunds received by India subsidiaries in 2021.
3. Current trade and other receivables increased in 2021 in line with the higher revenues.
4. Other financial assets decreased with the withdrawal of RM17.3 million fixed deposits with tenor of more than 3 months.
5. Assets classified as held for sale decreased due to PLife REIT's divestment of an industrial property in Japan on 29 January 2021 and disposal of the Group's investment in Apollo Gleneagles Hospital Ltd on 22 April 2021.

Assets and liabilities classified as held for sale also decreased due to change in exit plans for the Group's investments in AAHL from selling the Group's equity stake to winding down the operations of AAHL. Accordingly, the assets and liabilities of AAHL are no longer classified as held for sale.

6. Loans and borrowings decreased mainly due to repayment of loans.
7. On 30 March 2021, SRL Diagnostics Private Limited ("SRL"), Fortis Healthcare Limited ("Fortis") and certain non-controlling interests of SRL signed an amendment to their shareholders' agreement whereby, amongst other things, the certain non-controlling interests of SRL have agreed not to exercise their cash put option over SRL ("SRL Put Option") for a further period of 36 months from 5 February 2021. Accordingly, the SRL Put Option with a carrying value of RM909.4 million was classified as non-current trade and other payables as at 30 June 2021. The carrying value of the SRL Put Option was RM791.2 million as at 31 December 2020 and was classified as current trade and other payables.

### Note:

Key closing exchange rates used to translate the financial position of overseas subsidiaries into RM:

|       | 30 Jun 2021 | 31 Dec 2020 |
|-------|-------------|-------------|
| 1 SGD | 3.0979      | 3.0637      |
| 1 TL  | 0.4774      | 0.5453      |

**UNAUDITED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY FOR THE FINANCIAL PERIOD ENDED 30 JUNE 2021**

|  | Attributable to owners of the Company |                                |                               |                         |                                   |                           |                         | Non-distributable                              |                             |                 |                                |                                     | Distributable          |  |
|--|---------------------------------------|--------------------------------|-------------------------------|-------------------------|-----------------------------------|---------------------------|-------------------------|--|-----------------------------|-----------------|--------------------------------|-------------------------------------|------------------------|--|
|  | Share capital<br>RM'000               | Share option reserve<br>RM'000 | Revaluation reserve<br>RM'000 | Hedge reserve<br>RM'000 | Cost of hedging reserve<br>RM'000 | Capital reserve<br>RM'000 | Legal reserve<br>RM'000 | Foreign currency translation reserve<br>RM'000 | Retained earnings<br>RM'000 | Total<br>RM'000 | Perpetual securities<br>RM'000 | Non-controlling interests<br>RM'000 | Total equity<br>RM'000 |  |
| At 1 January 2021  | 19,473,364                            | 80,168                         | 83,434                        | 12,454                  | 408                               | (3,777,228)               | 55,590                  | 1,556,893                                      | 4,254,736                   | 21,739,819      | 2,158,061                      | 3,137,489                           | 27,035,369             |  |
| Foreign currency translation differences from foreign operations                         | -                                     | -                              | -                             | -                       | -                                 | -                         | -                       | 5,823  | -                           | 5,823           | -                              | (27,627)                            | (21,804)               |  |
| Realisation of FCTR upon disposal of a joint venture                                     | -                                     | -                              | -                             | -                       | -                                 | -                         | -                       | 22,148   | -                           | 22,148          | -                              | -                                   | 22,148                 |  |
| Hedge of net investments in foreign operations   | -                                     | -                              | -                             | -                       | -                                 | -                         | -                       | 13,974   | -                           | 13,974          | -                              | 25,296                              | 39,270                 |  |
| Cash flow hedge  | -                                     | -                              | -                             | 2,998                   | -                                 | -                         | -                       | -  | -                           | 2,998           | -                              | 5,428                               | 8,426                  |  |
| Cost of hedging reserve  | -                                     | -                              | -                             | -                       | 132                               | -                         | -                       | -  | -                           | 132             | -                              | 238                                 | 370                    |  |
| Remeasurement of defined benefit liabilities   | -                                     | -                              | -                             | -                       | -                                 | -                         | -                       | -  | 766                         | 766             | -                              | 393                                 | 1,159                  |  |
| Total other comprehensive income for the period  | -                                     | -                              | -                             | 2,998                   | 132                               | -                         | -                       | 41,945   | 766                         | 45,841          | -                              | 3,728                               | 49,569                 |  |
| Profit for the period  | -                                     | -                              | -                             | -                       | -                                 | -                         | -                       | -  | 858,927                     | 858,927         | -                              | 120,044                             | 978,971                |  |
| Total comprehensive income for the period  | -                                     | -                              | -                             | 2,998                   | 132                               | -                         | -                       | 41,945   | 859,693                     | 904,768         | -                              | 123,772                             | 1,028,540              |  |
| Contributions by and distributions to owners   |                                       |                                |                               |                         |                                   |                           |                         |  |                             |                 |                                |                                     |                        |  |
| Share-based payment transactions   | -                                     | 4,832                          | -                             | -                       | -                                 | 7                         | -                       | -  | -                           | 4,839           | -                              | 16                                  | 4,855                  |  |
| Dividends to owners of the Company   | -                                     | -                              | -                             | -                       | -                                 | -                         | -                       | -  | (351,163)                   | (351,163)       | -                              | -                                   | (351,163)              |  |
| Transfer to share capital for share options exercised                                    | 10,127                                | (10,127)                       | -                             | -                       | -                                 | -                         | -                       | -  | -                           | -               | -                              | -                                   | -                      |  |
| Cancellation of vested share options   | -                                     | (1,528)                        | -                             | -                       | -                                 | -                         | -                       | -  | 1,528                       | -               | -                              | -                                   | -                      |  |
| Changes in ownership interests in subsidiaries   | -                                     | -                              | -                             | 1                       | -                                 | 954                       | -                       | (6)  | -                           | 949             | -                              | 1,422                               | 2,371                  |  |
| Issue of shares by a subsidiary to non-controlling interests                             | -                                     | -                              | -                             | -                       | -                                 | -                         | -                       | -  | -                           | -               | -                              | 477                                 | 477                    |  |
| Transfer per statutory requirements  | -                                     | -                              | -                             | -                       | -                                 | -                         | 2,423                   | -  | (2,423)                     | -               | -                              | -                                   | -                      |  |
| Changes in fair value of liabilities on put options granted to non-controlling interests | -                                     | -                              | -                             | -                       | -                                 | (57,085)                  | -                       | -  | -                           | (57,085)        | -                              | (86,797)                            | (143,882)              |  |
| Dividends to non-controlling interests   | -                                     | -                              | -                             | -                       | -                                 | -                         | -                       | -  | -                           | -               | -                              | (102,952)                           | (102,952)              |  |
| Payment of coupon on perpetual securities  | -                                     | -                              | -                             | -                       | -                                 | 1,457                     | -                       | -  | -                           | 1,457           | (44,431)                       | -                                   | (42,974)               |  |
| Accrued perpetual securities distribution  | -                                     | -                              | -                             | -                       | -                                 | -                         | -                       | -  | (43,285)                    | (43,285)        | 43,285                         | -                                   | -                      |  |
| Total transactions with owners   | 10,127                                | (6,823)                        | -                             | 1                       | -                                 | (54,667)                  | 2,423                   | (6)  | (395,343)                   | (444,288)       | (1,146)                        | (187,834)                           | (633,268)              |  |
| At 30 June 2021  | 19,483,491                            | 73,345                         | 83,434                        | 15,453                  | 540                               | (3,831,895)               | 58,013                  | 1,598,832                                      | 4,719,086                   | 22,200,299      | 2,156,915                      | 3,073,427                           | 27,430,641             |  |

**UNAUDITED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY FOR THE FINANCIAL PERIOD ENDED 30 JUNE 2021**

|   | Attributable to owners of the Company |                                |                               |                         |                                   |                           |                         |  |                             |                 |                                |                                     |                        |
|---|---------------------------------------|--------------------------------|-------------------------------|-------------------------|-----------------------------------|---------------------------|-------------------------|--|-----------------------------|-----------------|--------------------------------|-------------------------------------|------------------------|
|   | Non-distributable                     |                                |                               |                         |                                   |                           |                         | Distributable                                  |                             |                 |                                |                                     |                        |
|   | Share capital<br>RM'000               | Share option reserve<br>RM'000 | Revaluation reserve<br>RM'000 | Hedge reserve<br>RM'000 | Cost of hedging reserve<br>RM'000 | Capital reserve<br>RM'000 | Legal reserve<br>RM'000 | Foreign currency translation reserve<br>RM'000 | Retained earnings<br>RM'000 | Total<br>RM'000 | Perpetual securities<br>RM'000 | Non-controlling interests<br>RM'000 | Total equity<br>RM'000 |
| At 1 January 2020   | 19,455,138                            | 83,500                         | 83,434                        | 15,251                  | 325                               | (3,708,985)               | 53,091                  | 1,943,889                                      | 4,413,888                   | 22,339,531      | 2,158,169                      | 3,596,269                           | 28,093,969             |
| Foreign currency translation differences from foreign operations                        | -                                     | -                              | -                             | -                       | -                                 | -                         | -                       | (75,057)                                       | -                           | (75,057)        | -                              | (16,525)                            | (91,582)               |
| Realisation of FCTR upon substantive liquidation of a joint venture                     | -                                     | -                              | -                             | -                       | -                                 | -                         | -                       | 60,419   | -                           | 60,419          | -                              | -                                   | 60,419                 |
| Hedge of net investments in foreign operations  | -                                     | -                              | -                             | -                       | -                                 | -                         | -                       | (30,280)                                       | -                           | (30,280)        | -                              | (54,751)                            | (85,031)               |
| Cash flow hedge   | -                                     | -                              | -                             | (3,241)                 | -                                 | -                         | -                       | -  | -                           | (3,241)         | -                              | (5,867)                             | (9,108)                |
| Cost of hedging reserve   | -                                     | -                              | -                             | -                       | (27)                              | -                         | -                       | -  | -                           | (27)            | -                              | (48)                                | (75)                   |
| Remeasurement of defined benefit liabilities  | -                                     | -                              | -                             | -                       | -                                 | -                         | -                       | -  | (1,089)                     | (1,089)         | -                              | (3,484)                             | (4,573)                |
| Total other comprehensive income for the period   | -                                     | -                              | -                             | (3,241)                 | (27)                              | -                         | -                       | (44,918)                                       | (1,089)                     | (49,275)        | -                              | (80,675)                            | (129,950)              |
| Loss for the period   | -                                     | -                              | -                             | -                       | -                                 | -                         | -                       | -  | (440,428)                   | (440,428)       | -                              | (158,378)                           | (598,806)              |
| Total comprehensive income for the period   | -                                     | -                              | -                             | (3,241)                 | (27)                              | -                         | -                       | (44,918)                                       | (441,517)                   | (489,703)       | -                              | (239,053)                           | (728,756)              |
| Contributions by and distributions to owners  |                                       |                                |                               |                         |                                   |                           |                         |  |                             |                 |                                |                                     |                        |
| Share-based payment transactions  | -                                     | 17,925                         | -                             | -                       | -                                 | 128                       | -                       | -  | -                           | 18,053          | -                              | 283                                 | 18,336                 |
| Dividends to owners of the Company  | -                                     | -                              | -                             | -                       | -                                 | -                         | -                       | -  | (350,960)                   | (350,960)       | -                              | -                                   | (350,960)              |
| Transfer to share capital for share options exercised                                   | 18,225                                | (18,225)                       | -                             | -                       | -                                 | -                         | -                       | -  | -                           | -               | -                              | -                                   | -                      |
| Cancellation of vested share options  | -                                     | (5,360)                        | -                             | -                       | -                                 | -                         | -                       | -  | 5,360                       | -               | -                              | -                                   | -                      |
| Changes in ownership interests in subsidiaries  | -                                     | -                              | -                             | 1                       | -                                 | 943                       | -                       | 2  | -                           | 946             | -                              | 391                                 | 1,337                  |
| Issue of shares by subsidiaries to non-controlling interests                            | -                                     | -                              | -                             | -                       | -                                 | -                         | -                       | -  | -                           | -               | -                              | 259                                 | 259                    |
| Transfer per statutory requirements   | -                                     | -                              | -                             | -                       | -                                 | -                         | 2,563                   | -  | (2,563)                     | -               | -                              | -                                   | -                      |
| Change in fair value of liabilities on put options granted to non-controlling interests | -                                     | -                              | -                             | -                       | -                                 | (20,403)                  | -                       | -  | -                           | (20,403)        | -                              | (3,005)                             | (23,408)               |
| Dividends to non-controlling interests  | -                                     | -                              | -                             | -                       | -                                 | -                         | -                       | -  | -                           | -               | -                              | (80,537)                            | (80,537)               |
| Payment of coupon on perpetual securities   | -                                     | -                              | -                             | -                       | -                                 | 630                       | -                       | -  | -                           | 630             | (44,214)                       | -                                   | (43,584)               |
| Accrued perpetual securities distribution   | -                                     | -                              | -                             | -                       | -                                 | -                         | -                       | -  | (45,314)                    | (45,314)        | 45,314                         | -                                   | -                      |
| Total transactions with owners  | 18,225                                | (5,660)                        | -                             | 1                       | -                                 | (18,702)                  | 2,563                   | 2  | (393,477)                   | (397,048)       | 1,100                          | (82,609)                            | (478,557)              |
| At 30 June 2020   | 19,473,363                            | 77,840                         | 83,434                        | 12,011                  | 298                               | (3,727,687)               | 55,654                  | 1,898,973                                      | 3,578,894                   | 21,452,780      | 2,159,269                      | 3,274,607                           | 26,886,656             |

The unaudited Consolidated Statement of Changes in Equity should be read in conjunction with the 2020 Audited Financial Statements and the accompanying explanatory notes attached to this financial report.

**UNAUDITED CONSOLIDATED STATEMENT OF CASH FLOWS  
FOR THE FINANCIAL PERIOD ENDED 30 JUNE 2021**

|   | <b>Financial period ended</b> |                    |
|---|-------------------------------|--------------------|
|   | <b>30 Jun 2021</b>            | <b>30 Jun 2020</b> |
|   | <b>RM'000</b>                 | <b>RM'000</b>      |
| <b>Cash flows from operating activities</b>                                   |                               |                    |
| Profit/(Loss) before tax  | 1,254,960                     | (489,389)          |
| Adjustments for:  |                               |                    |
| Dividend income   | (1,288)                       | (3,362)            |
| Finance income  | (188,949)                     | (130,916)          |
| Finance costs   | 416,934                       | 505,990            |
| Depreciation and impairment of property, plant and equipment                  | 619,501                       | 473,986            |
| Depreciation of ROU assets  | 155,153                       | 175,563            |
| Amortisation and impairment of intangible assets                              | 24,167                        | 31,286             |
| Impairment loss made/(written back):  |                               |                    |
| - Goodwill  | -                             | 399,153            |
| - Trade and other receivables   | 61,450                        | 41,484             |
| - Inventories   | (159)                         | 436                |
| Write-off:  |                               |                    |
| - Property, plant and equipment   | 916                           | 896                |
| - Trade and other receivables   | 6,564                         | 3,418              |
| - Inventories   | 1,804                         | 1,541              |
| Remeasurement to fair value of interest in a joint venture                    | (85,768)                      | -                  |
| Gain on disposal of property, plant and equipment                             | (1,489)                       | (4,807)            |
| Gain on disposal of an investment property                                    | (15,722)                      | -                  |
| Gain on disposal of a subsidiary  | -                             | (13,188)           |
| Gain on disposal of a joint venture   | (139,053)                     | -                  |
| Realisation of FCTR upon substantive liquidation of a joint venture           | -                             | 60,419             |
| Provision for loan taken by a joint venture                                   | -                             | 2,441              |
| Share of profits of associates (net of tax)                                   | (18,331)                      | (1,991)            |
| Share of (profits)/losses of joint ventures (net of tax)                      | (8,045)                       | 3,914              |
| Equity-settled share-based payment  | 4,855                         | 18,336             |
| Net unrealised foreign exchange differences                                   | 2,347                         | (11,923)           |
| <b>Operating profit before changes in working capital</b>                     | <b>2,089,847</b>              | <b>1,063,287</b>   |
| Changes in working capital:   |                               |                    |
| Trade and other receivables   | (490,634)                     | 138,789            |
| Development properties  | (3,095)                       | (5,514)            |
| Inventories   | (44,875)                      | (46,695)           |
| Trade and other payables  | 109,662                       | (271,954)          |
| <b>Cash generated from operations</b>   | <b>1,660,905</b>              | <b>877,913</b>     |
| Tax paid  | (208,997)                     | (149,447)          |
| <b>Net cash from operating activities</b>                                     | <b>1,451,908</b>              | <b>728,466</b>     |
| <b>Cash flows from investing activities</b>                                   |                               |                    |
| Interest received   | 28,764                        | 28,284             |
| Acquisition of a subsidiary, net of cash and cash equivalents acquired        | (178,042)                     | -                  |
| Acquisition of a business, net of cash and cash equivalents acquired          | -                             | (594)              |
| Development and purchase of intangible assets                                 | (9,693)                       | (9,341)            |
| Purchase of property, plant and equipment                                     | (394,554)                     | (413,748)          |
| Purchase of investment properties   | (5,093)                       | (5,067)            |
| Purchase of equity investments  | -                             | (28,539)           |
| Net cash inflow from disposal of a subsidiary                                 | -                             | 13,368             |
| Net withdrawal/(placement) of fixed deposits with tenor of more than 3 months | 17,327                        | (8,002)            |
| Proceeds from disposal of property, plant and equipment                       | 7,734                         | 10,749             |
| Proceeds from disposal of an investment property                              | 110,414                       | -                  |
| Proceeds from disposal of intangible assets                                   | 1,170                         | 490                |
| Proceeds from disposal of a joint venture                                     | 225,080                       | -                  |
| Repayment by a joint venture  | 9,638                         | -                  |
| Dividends received from associates  | 14,251                        | -                  |
| Dividends received from joint ventures  | 16,330                        | 428                |
| <b>Net cash used in investing activities</b>                                  | <b>(156,674)</b>              | <b>(411,972)</b>   |

**UNAUDITED CONSOLIDATED STATEMENT OF CASH FLOWS  
FOR THE FINANCIAL PERIOD ENDED 30 JUNE 2021**

|  | <b>Financial period ended</b> |                    |
|--|-------------------------------|--------------------|
|  | <b>30 Jun 2021</b>            | <b>30 Jun 2020</b> |
|  | <b>RM'000</b>                 | <b>RM'000</b>      |
| <b>Cash flows from financing activities</b>                            |                               |                    |
| Interest paid  | (152,847)                     | (172,697)          |
| Proceeds from loans and borrowings                                     | 894,568                       | 1,716,079          |
| Repayment of loans and borrowings                                      | (1,538,897)                   | (1,597,419)        |
| Payment of perpetual securities distribution                           | (42,974)                      | (43,584)           |
| Payment of lease liabilities   | (165,285)                     | (191,337)          |
| Dividends paid to shareholders   | (351,163)                     | (350,960)          |
| Dividends paid to non-controlling interests                            | (102,952)                     | (80,537)           |
| Capital injection by non-controlling interests                         | 846                           | 259                |
| Change in restricted cash  | 5,605                         | (7,662)            |
| <b>Net cash used in financing activities</b>                           | <b>(1,453,099)</b>            | <b>(727,858)</b>   |
| <b>Net decrease in cash and cash equivalents</b>                       | <b>(157,865)</b>              | <b>(411,364)</b>   |
| Effect of exchange rate fluctuations on cash and cash equivalents held | 19,218                        | 54,865             |
| Cash and cash equivalents at beginning of the period                   | 2,264,047                     | 2,641,463          |
| <b>Cash and cash equivalents at end of the period</b>                  | <b>2,125,400</b>              | <b>2,284,964</b>   |

***Cash and cash equivalents***

Cash and cash equivalents in the statement of cash flows comprises the following amounts from the statement of financial position:

|   | <b>30 Jun 2021</b> | <b>30 Jun 2020</b> |
|---|--------------------|--------------------|
|   | <b>RM'000</b>      | <b>RM'000</b>      |
| Cash and bank balances                                | 1,408,515          | 1,254,392          |
| Fixed deposits with tenor of 3 months or less         | 2,646,120          | 3,026,122          |
|   | 4,054,635          | 4,280,514          |
| Less:   |                    |                    |
| - Bank overdrafts                                     | (37,322)           | (84,968)           |
| - Deposits placed in escrow account                   | (1,883,255)        | (1,897,092)        |
| - Restricted cash                                     | (8,658)            | (13,490)           |
| <b>Cash and cash equivalents at end of the period</b> | <b>2,125,400</b>   | <b>2,284,964</b>   |

**A NOTES TO THE INTERIM FINANCIAL REPORT  
FOR THE SECOND QUARTER AND FINANCIAL PERIOD ENDED 30 JUNE 2021**

**A1 BASIS OF PREPARATION**

**a) Basis of accounting**

These consolidated financial report are unaudited and prepared in accordance with the applicable disclosure provisions of the Main Market Listing Requirements of Bursa Malaysia Securities Berhad, MFRS 134: *Interim Financial Reporting* in Malaysia and IAS 34: *Interim Financial Reporting*. They do not include all of the information required for full annual financial statements and should be read in conjunction with the audited consolidated financial statements of the Group for the financial year ended 31 December 2020 ("2020 Audited Financial Statements").

The 2020 Audited Financial Statements were prepared under Malaysian Financial Reporting Standards ("MFRSs").

**b) Significant accounting policies**

The accounting policies and presentation adopted for this unaudited consolidated interim financial report are consistent with those adopted for the 2020 Audited Financial Statements, except for the adoption of the following new, revised and amendments to MFRS as issued by the Malaysian Accounting Standards Board.

MFRSs, interpretations and amendments effective for annual periods beginning on or after 1 January 2021

- Amendments to MFRS 9, *Financial Instruments*, MFRS 139, *Financial Instruments: Recognition and Measurement*, MFRS 7, *Financial Instruments: Disclosures* and MFRS 16, *Leases – Interest Rate Benchmark Reform – Phase 2*

MFRSs, interpretations and amendments effective for annual periods beginning on or after 1 April 2021

- Amendment to MFRS 16, *Leases – Covid-19-Related Rent Concessions beyond 30 June 2021*

The Group had elected to early adopt the Amendments to MFRS 16, *Leases – Covid-19-Related Rent Concessions beyond 30 June 2021*. Consequently, rent concessions received, if any, have been recognised in profit or loss.

**A2 AUDIT REPORT OF THE PRECEDING ANNUAL FINANCIAL STATEMENTS**

The audited financial statements for the financial year ended 31 December 2020 were not subjected to any qualification.

**A3 SEASONALITY OF OPERATIONS**

Inpatient and outpatient revenue and volume are generally lower during festive periods and summer months in each of the relevant countries in which the Group operates and other holiday periods. Conversely, patient volumes and thus inpatient and outpatient revenue are highest during the winter months in some markets. As the Group is continuously expanding, the effects of seasonality may not be obvious from the Group's financial statements.

**A4 SIGNIFICANT UNUSUAL ITEMS AFFECTING ASSETS, LIABILITIES, EQUITY, NET INCOME OR CASH FLOWS**

There were no unusual items affecting assets, liabilities, equity, net income or cash flows due to their nature, size or incidence for the financial period ended 30 June 2021, other than the COVID-19 pandemic impact on the performance of the Group.

**A NOTES TO THE INTERIM FINANCIAL REPORT  
FOR THE SECOND QUARTER AND FINANCIAL PERIOD ENDED 30 JUNE 2021**

**A5 CHANGE IN ACCOUNTING ESTIMATES**

There were no changes in the estimates of amounts reported in prior financial years that may have a material effect in the current quarter and financial period.

In preparing the unaudited consolidated interim financial report, the significant judgments made by the management in applying the Group's accounting policies and key sources of estimating uncertainty were consistent with those applied to 2020 Audited Financial Statements.

**A6 DEBT AND EQUITY SECURITIES**

Between 1 January 2021 to 30 June 2021, IHH issued 1,854,000 new ordinary shares pursuant to the surrender of vested Long Term Incentive Plan ("LTIP") units.

The LTIP lapsed on 24 March 2021 and, accordingly, all the unvested LTIP units lapsed upon the expiry of the LTIP.

Except as disclosed above, there were no other issuance of shares, share buy-backs and repayments of debt and equity securities by IHH during the financial period 1 January 2021 to 30 June 2021.

As at 30 June 2021, the issued share capital of IHH comprised of 8,779,073,463 ordinary shares.

**A7 DIVIDENDS PAID**

|   | <b>Sen per<br/>ordinary share</b> | <b>Total amount<br/>RM'000</b> | <b>Date of<br/>payment</b> |
|---|-----------------------------------|--------------------------------|----------------------------|
| First and final single tier cash dividend for financial year ended 31 December 2020 | 4.00                              | 351,163                        | 30-Apr-21                  |

**A8 SEGMENT REPORTING**

There had been no significant changes in the basis of segmentation or in the basis of measurement of segment profit or loss from the 2020 Audited Financial Statements.

Management monitors the operating results of each business unit for the purpose of making decisions on resource allocation and performance assessment. Performance is measured based on segment earnings before interest, tax, depreciation, amortisation, exchange differences and other non-operational items ("EBITDA").

**A NOTES TO THE INTERIM FINANCIAL REPORT  
FOR THE SECOND QUARTER AND FINANCIAL PERIOD ENDED 30 JUNE 2021**

**A8 SEGMENT REPORTING**

Financial period ended 30 June 2021

|   | Parkway Pantai <sup>1</sup> |                    |                 |                            |                                   | Acibadem<br>Holdings       | IMU<br>Health      |                                   |                  |                        |                 |
|---|-----------------------------|--------------------|-----------------|----------------------------|-----------------------------------|----------------------------|--------------------|-----------------------------------|------------------|------------------------|-----------------|
|   | Singapore<br>RM'000         | Malaysia<br>RM'000 | India<br>RM'000 | Greater<br>China<br>RM'000 | PPL Others <sup>2</sup><br>RM'000 | CEE <sup>3</sup><br>RM'000 | Malaysia<br>RM'000 | PLife REIT <sup>1</sup><br>RM'000 | Others<br>RM'000 | Eliminations<br>RM'000 | Total<br>RM'000 |
| <b><u>Revenue and expenses</u></b>                              |                             |                    |                 |                            |                                   |                            |                    |                                   |                  |                        |                 |
| Revenue from external customers                                 | 2,417,345                   | 1,274,287          | 1,803,356       | 406,178                    | 2,844                             | 2,113,797                  | 122,056            | 74,900                            | 1,288            | -                      | 8,216,051       |
| Inter-segment revenue   | 55,745                      | 500                | 37              | -                          | 382,968                           | -                          | 1,335              | 107,815                           | 349,859          | (898,259)              | -               |
| Total segment revenue   | 2,473,090                   | 1,274,787          | 1,803,393       | 406,178                    | 385,812                           | 2,113,797                  | 123,391            | 182,715                           | 351,147          | (898,259)              | 8,216,051       |
| EBITDA  | 890,270                     | 336,132            | 304,268         | (50,080)                   | (13,451)                          | 580,385                    | 44,753             | 162,394                           | 311,160          | (496,551)              | 2,069,280       |
| Depreciation and impairment of<br>property, plant and equipment | (84,309)                    | (105,876)          | (75,532)        | (237,059)                  | (27)                              | (98,158)                   | (6,593)            | (11,807)                          | (140)            | -                      | (619,501)       |
| Depreciation of ROU assets                                      | (143,898)                   | (12,880)           | (16,393)        | (37,021)                   | (7)                               | (42,300)                   | (2,206)            | (6,347)                           | (493)            | 106,392                | (155,153)       |
| Amortisation of intangible assets                               | -                           | (1,818)            | (13,316)        | (1,963)                    | -                                 | (6,748)                    | (322)              | -                                 | -                | -                      | (24,167)        |
| Foreign exchange differences                                    | (175)                       | (43)               | 640             | 464                        | (202)                             | 161                        | -                  | 3,668                             | 14               | -                      | 4,527           |
| Finance income  | 193                         | 5,107              | 8,199           | 2,782                      | 2,715                             | 161,996                    | 1,221              | 8,682                             | 1,187            | (3,133)                | 188,949         |
| Finance costs   | (7,638)                     | (375)              | (60,043)        | (33,537)                   | (10,268)                          | (304,885)                  | -                  | (6,569)                           | (739)            | 7,120                  | (416,934)       |
| Share of profits of associates (net of tax)                     | 1,550                       | -                  | 5,705           | -                          | 11,076                            | -                          | -                  | -                                 | -                | -                      | 18,331          |
| Share of profits of joint ventures (net of tax)                 | 383                         | -                  | 7,662           | -                          | -                                 | -                          | -                  | -                                 | -                | -                      | 8,045           |
| Others  | -                           | -                  | 224,821         | -                          | (43,238)                          | -                          | -                  | -                                 | -                | -                      | 181,583         |
| Profit/(Loss) before tax  | 656,376                     | 220,247            | 386,011         | (356,414)                  | (53,402)                          | 290,451                    | 36,853             | 150,021                           | 310,989          | (386,172)              | 1,254,960       |
| Income tax expense  | (115,361)                   | (52,627)           | (56,586)        | (1,676)                    | (3,576)                           | (23,167)                   | (9,748)            | (12,512)                          | (736)            | -                      | (275,989)       |
| Profit/(Loss) for the period                                    | 541,015                     | 167,620            | 329,425         | (358,090)                  | (56,978)                          | 267,284                    | 27,105             | 137,509                           | 310,253          | (386,172)              | 978,971         |
| <b><u>Assets and liabilities</u></b>                            |                             |                    |                 |                            |                                   |                            |                    |                                   |                  |                        |                 |
| Cash and cash equivalents                                       | 207,005                     | 504,812            | 1,984,953       | 379,628                    | 492,490                           | 238,714                    | 26,065             | 93,006                            | 127,962          | -                      | 4,054,635       |
| Other assets  | 13,111,537                  | 6,096,322          | 7,543,143       | 3,823,140                  | 2,163,858                         | 4,752,314                  | 576,051            | 4,747,117                         | 217,060          | (2,541,719)            | 40,488,823      |
| Segment assets as at 30 June 2021                               | 13,318,542                  | 6,601,134          | 9,528,096       | 4,202,768                  | 2,656,348                         | 4,991,028                  | 602,116            | 4,840,123                         | 345,022          | (2,541,719)            | 44,543,458      |
| Loans and borrowings  | -                           | -                  | 919,310         | 3,051,691                  | 783,095                           | 1,882,096                  | 30,740             | 2,303,128                         | -                | -                      | 8,970,060       |
| Other liabilities   | 3,732,693                   | 747,179            | 2,524,163       | 1,035,294                  | 141,890                           | 1,840,066                  | 155,143            | 372,767                           | 49,452           | (2,455,890)            | 8,142,757       |
| Segment liabilities as at 30 June 2021                          | 3,732,693                   | 747,179            | 3,443,473       | 4,086,985                  | 924,985                           | 3,722,162                  | 185,883            | 2,675,895                         | 49,452           | (2,455,890)            | 17,112,817      |

Note:

1 Parkway Pantai Group, per the corporate structure, comprises of “Parkway Pantai” and “PLife REIT” segments

2 “PPL Others” comprises of mainly Parkway Pantai’s hospital in Brunei, corporate office as well as other investment holding entities within Parkway Pantai

3 “CEE” refers to Central and Eastern Europe

**A NOTES TO THE INTERIM FINANCIAL REPORT  
FOR THE SECOND QUARTER AND FINANCIAL PERIOD ENDED 30 JUNE 2021**

Financial period ended 30 June 2020

|  | Parkway Pantai <sup>1</sup> |                    |                 |                            |                                   | Acibadem<br>Holdings<br>CEE <sup>3</sup> | IMU<br>Health<br>Malaysia | PLife REIT <sup>1</sup> | Others  | Eliminations | Total      |
|--|-----------------------------|--------------------|-----------------|----------------------------|-----------------------------------|--|---------------------------|-------------------------|---------|--------------|------------|
|  | Singapore<br>RM'000         | Malaysia<br>RM'000 | India<br>RM'000 | Greater<br>China<br>RM'000 | PPL Others <sup>2</sup><br>RM'000 | RM'000                                   | RM'000                    | RM'000                  | RM'000  | RM'000       | RM'000     |
| <b><u>Revenue and expenses</u></b>                       |                             |                    |                 |                            |                                   |  |                           |                         |         |              |            |
| Revenue from external customers                          | 1,820,691                   | 989,747            | 1,167,185       | 281,668                    | 80,261                            | 1,569,635                                | 130,527                   | 77,210                  | 3,362   | -            | 6,120,286  |
| Inter-segment revenue                                    | 52,920                      | 500                | -               | -                          | 626                               | -  | 1,679                     | 105,335                 | 389,453 | (550,513)    | -          |
| Total segment revenue                                    | 1,873,611                   | 990,247            | 1,167,185       | 281,668                    | 80,887                            | 1,569,635                                | 132,206                   | 182,545                 | 392,815 | (550,513)    | 6,120,286  |
| EBITDA   | 588,402                     | 221,580            | (4,365)         | (115,515)                  | 11,093                            | 291,712                                  | 51,276                    | 143,713                 | 344,937 | (530,839)    | 1,001,994  |
| Depreciation of property, plant and equipment            | (79,705)                    | (91,141)           | (83,899)        | (89,238)                   | (2,575)                           | (111,324)                                | (5,975)                   | (9,976)                 | (153)   | -            | (473,986)  |
| Depreciation of ROU assets                               | (139,927)                   | (10,709)           | (22,650)        | (36,124)                   | (3,335)                           | (52,601)                                 | (2,423)                   | (8,051)                 | (9)     | 100,266      | (175,563)  |
| Amortisation and impairment of intangible assets         | (1,821)                     | (355)              | (16,841)        | (3,434)                    | -                                 | (8,513)                                  | (322)                     | -                       | -       | -            | (31,286)   |
| Foreign exchange differences                             | 419                         | (123)              | 3,487           | 206                        | 5,268                             | 95                                       | 34                        | (256)                   | 6,144   | -            | 15,274     |
| Finance income   | 329                         | 12,971             | 5,747           | 30,082                     | 7,144                             | 106,119                                  | 1,954                     | 14                      | 43      | (33,487)     | 130,916    |
| Finance costs  | (12,987)                    | (2,785)            | (74,615)        | (74,954)                   | (16,838)                          | (349,367)                                | 337                       | (13,098)                | (1,760) | 40,077       | (505,990)  |
| Share of profits/(losses) of associates (net of tax)     | 667                         | -                  | 1,593           | -                          | -                                 | (269)                                    | -                         | -                       | -       | -            | 1,991      |
| Share of profits/(losses) of joint ventures (net of tax) | 428                         | -                  | (3,508)         | (834)                      | -                                 | -  | -                         | -                       | -       | -            | (3,914)    |
| Others   | -                           | -                  | (462,012)       | -                          | -                                 | 13,188                                   | -                         | -                       | (1)     | -            | (448,825)  |
| Profit/(Loss) before tax                                 | 355,805                     | 129,438            | (657,063)       | (289,811)                  | 757                               | (110,960)                                | 44,881                    | 112,346                 | 349,201 | (423,983)    | (489,389)  |
| Income tax expense                                       | (53,274)                    | (32,184)           | (13,379)        | (4,040)                    | (10,819)                          | 27,551                                   | (11,480)                  | (10,560)                | (1,232) | -            | (109,417)  |
| Profit/(Loss) for period                                 | 302,531                     | 97,254             | (670,442)       | (293,851)                  | (10,062)                          | (83,409)                                 | 33,401                    | 101,786                 | 347,969 | (423,983)    | (598,806)  |
| <b><u>Assets and liabilities</u></b>                     |                             |                    |                 |                            |                                   |  |                           |                         |         |              |            |
| Cash and cash equivalents                                | 190,740                     | 860,506            | 1,985,589       | 468,066                    | 293,475                           | 206,053                                  | 20,109                    | 95,486                  | 160,490 | -            | 4,280,514  |
| Other assets   | 13,051,788                  | 5,024,053          | 7,322,965       | 3,882,896                  | 2,840,776                         | 5,132,620                                | 523,850                   | 4,807,534               | 211,938 | (3,142,882)  | 39,655,538 |
| Segment assets as at 30 June 2020                        | 13,242,528                  | 5,884,559          | 9,308,554       | 4,350,962                  | 3,134,251                         | 5,338,673                                | 543,959                   | 4,903,020               | 372,428 | (3,142,882)  | 43,936,052 |
| Loans and borrowings                                     | 3,073                       | -                  | 1,038,174       | 2,841,308                  | 792,333                           | 2,192,684                                | 4,501                     | 2,385,694               | -       | -            | 9,257,767  |
| Other liabilities  | 4,870,341                   | 642,295            | 2,254,530       | 899,686                    | (268,500)                         | 1,964,676                                | 134,643                   | 402,100                 | 34,740  | (3,142,882)  | 7,791,629  |
| Segment liabilities as at 30 June 2020                   | 4,873,414                   | 642,295            | 3,292,704       | 3,740,994                  | 523,833                           | 4,157,360                                | 139,144                   | 2,787,794               | 34,740  | (3,142,882)  | 17,049,396 |

Note:

1 Parkway Pantai Group, per the corporate structure, comprises of "Parkway Pantai" and "PLife REIT" segments

2 "PPL Others" comprises of mainly Parkway Pantai's hospital in Brunei, corporate office as well as other investment holding entities within Parkway Pantai

3 "CEE" refers to Central and Eastern Europe

**A NOTES TO THE INTERIM FINANCIAL REPORT  
FOR THE SECOND QUARTER AND FINANCIAL PERIOD ENDED 30 JUNE 2021**

**A9 VALUATION OF PROPERTY, PLANT AND EQUIPMENT**

The Group does not adopt a revaluation policy on its property, plant and equipment.

**A10 SIGNIFICANT RELATED PARTY TRANSACTIONS**

Related party transactions have been entered into in the normal course of business under negotiated terms. Other than the remuneration paid to the Key Management Personnel, the significant related party transactions of the Group are as follows:

|   | <b>Financial period ended</b> |                    |
|---|-------------------------------|--------------------|
|   | <b>30 Jun 2021</b>            | <b>30 Jun 2020</b> |
|   | <b>RM'000</b>                 | <b>RM'000</b>      |
| <b>Transactions with substantial shareholders and their related companies</b> |                               |                    |
| - Sales and provision of services   | 98                            | 110                |
| - Purchase and consumption of services  | (5,888)                       | (3,268)            |
|   | <hr/>                         | <hr/>              |
| <b>Transactions with Key Management Personnel and their related companies</b> |                               |                    |
| - Sales and provision of services   | 1,190                         | 1,329              |
| - Purchase and consumption of services  | (33,365)                      | (26,280)           |
|   | <hr/>                         | <hr/>              |

**A NOTES TO THE INTERIM FINANCIAL REPORT  
FOR THE SECOND QUARTER AND FINANCIAL PERIOD ENDED 30 JUNE 2021**

**A11 CHANGES IN THE COMPOSITION OF THE GROUP**

- (a) On 4 February 2021, Medical Resources International Pte Ltd (“MRI”) increased its interest in Chengdu Shenton Health Clinic Co., Ltd (“Chengdu Shenton Clinic”) following MRI’s cash contribution of RMB1.41 million (equivalent to RM885,000) to the registered capital of Chengdu Shenton Clinic. Post the cash contribution, MRI’s interest in Chengdu Shenton Clinic increased from 60.95% to 61.75%.
- (b) On 4 March 2021, MRI increased its interest in Chengdu Shenton Clinic following the conversion of the shareholder’s loan of RMB1.41 million (equivalent to RM885,000) to the registered capital of Chengdu Shenton Clinic. Post the conversion of the shareholder’s loan, MRI’s interest in Chengdu Shenton Clinic increased from 61.75% to 62.42%.
- (c) On 5 April 2021, Parkway Trust Management Limited (“PTM”) transferred 130,600 Parkway Life Real Estate Investment Trust (“PLife REIT”) units that it owned to its eligible employees in accordance to PTM’s long term incentive plan. Consequential thereto, IHH Group’s effective interest in PLife REIT was diluted from 35.62% to 35.60%.
- (d) On 5 April 2021, SRL Limited acquired the remaining 50% equity interest in DDRC SRL not already held by its wholly-owned subsidiary, SRL, for a total cash consideration of INR350.0 crore (equivalent to RM197.5 million). Post the acquisition, SRL Limited’s direct and indirect equity interest in DDRC SRL increased from 50% to 100% and DDRC SRL became an indirect subsidiary of IHH.

The effects of the acquisition are as follows:

|  | <b>Provisional<br/>RM’000</b> |
|--|-------------------------------|
| <b>Identifiable assets acquired and liabilities assumed</b>      |                               |
| Property, plant and equipment                                    | 24,436                        |
| Right-of-use assets  | 3,416                         |
| Intangible assets  | 160,448                       |
| Deferred tax assets  | 930                           |
| Other financial assets   | 29                            |
| Tax recoverables   | 1,013                         |
| Inventories  | 4,528                         |
| Trade and other receivables                                      | 14,237                        |
| Cash and cash equivalents  | 7,844                         |
| Lease liabilities  | (3,723)                       |
| Employee benefits  | (3,950)                       |
| Trade and other payables   | (8,461)                       |
| Deferred tax liabilities   | (39,207)                      |
| Fair value of net identifiable assets acquired                   | <u>161,540</u>                |
| <b>Net cash outflow arising from acquisition of subsidiaries</b> |                               |
| Purchase consideration in cash and cash equivalents              | 199,432                       |
| Less: deferred purchase consideration                            | (13,546)                      |
| Less: cash and cash equivalents acquired                         | <u>(7,844)</u>                |
|  | <u>178,042</u>                |
| <b>Goodwill</b>  |                               |
| Total purchase consideration                                     | 199,432                       |
| Fair value of pre-existing interest in the acquiree              | 199,432                       |
| Fair value of net identifiable assets acquired                   | <u>(161,540)</u>              |
| Goodwill   | <u>237,324</u>                |

As at 30 June 2021, the Group is in the midst of performing a purchase price allocation (“PPA”) for the acquisition of DDRC SRL, and would adjust goodwill accordingly upon the completion of the PPA.

**A NOTES TO THE INTERIM FINANCIAL REPORT  
FOR THE SECOND QUARTER AND FINANCIAL PERIOD ENDED 30 JUNE 2021**

- (e) On 3 May 2021, Acibadem Sağlık Hizmetleri ve Ticaret A.S. (“ASH”) established a wholly-owned subsidiary, LifeClub Sağlıkli Yaşam Hizmetleri A.Ş. (“LifeClub”) in Turkey. The initial capital of LifeClub is TL50,000 (equivalent to RM25,000) and its intended principal activity is providing e-consulting activities, wellness services and marketplace activities relating to all health-related products and memberships to its subscribers.
- (f) On 24 May 2021, ASH acquired the remaining 0.01% equity interest in Acibadem Poliklinikleri A.S. (“POL”) at no consideration. Post the acquisition, ASH’s equity interest in POL increased from 99.99% to 100%.
- (g) On 30 June 2021, Parkway Life Japan4 Pte Ltd (“TK Investor”) entered into a Tokumei Kumiai agreement (or silent partnership agreement, the “TK Agreement”) with Godo Kaisha Samurai 15 (the “TK Operator”). Pursuant to the TK Agreement, the purchase price of the properties amounting to JPY4.1 billion (equivalent to RM154,160,000) will be injected into the TK Operator by the TK Investor to facilitate the acquisition of two nursing homes by the TK Operator. PLife REIT does not have any direct or indirect equity in the TK Operator. However due to the nature of the arrangements under the TK Agreement, the TK Operator is under established terms that impose strict limitations on decision making powers of the TK Operator’s management, resulting in PLife REIT receiving the majority of the benefits relating to the TK Operator’s operations and net assets, being exposed to the majority of the risks incident to the TK Operator’s activities and retaining the majority of the residual or ownership risks related to the TK Operator and their assets. As such the TK Operator is regarded as indirect subsidiary of IHH pursuant to MFRS10 *Consolidated Financial Statements*.

The above changes in the composition of the Group are not expected to have material effect on the earnings and net assets of the Group.

**A12 SUBSEQUENT EVENTS**

- (a) On 12 July 2021, Integrated Healthcare Holdings (Bharat) Limited was struck off from the Register of Companies pursuant to Section 308 of the Mauritius Companies Act 2001.
- (b) On 20 July 2021, Acibadem City Clinic B.V. (“ACC BV”), acquired 70% equity interest in Opsta Bolnica Bel Medic (Bel Medic General Hospital) (“Bel Medic”) for a total consideration of EUR10.0 million (equivalent to RM49.0 million). Bel Medic is a private healthcare operator in Belgrade, Serbia and it currently operates a 54 bedded general hospital and 5 outpatient clinics. Post completion of the acquisition, the following entities have become indirect subsidiaries of ACC BV and thus have become indirect subsidiaries of the Company:
  - (i) Dom Zdravlja Bel Medic (Health Center);
  - (ii) Dom Zdravlja Bel Medic Slavija (Health Center Slavija); and
  - (iii) Bel Food & Coffee d.o.o.

**A13 CHANGES IN CONTINGENT LIABILITIES OR CONTINGENT ASSETS**

In 2019, Continental Hospitals Private Limited received letters from the Reserve Bank of India (“RBI”) pointing out certain non-compliances with Foreign Exchange Management Act 1999 (“FEMA”). RBI sought clarifications on the status of this matter before the Singapore Arbitral Tribunal. During the year, RBI has directed that the compounding application be re-submitted upon receipt of the final orders from the Singapore Arbitral Tribunal, where the dispute continues to remain pending. Arbitration has been deferred at the mutual request of the parties until 31 August 2021.

The financial implication of such non-compliances is currently unascertainable and will be known upon the acceptance and disposal of the compounding application by the RBI.

Except for above development to the contingent liabilities disclosed in Note 45 and 46 of the 2020 Audited Financial Statements, there were no other material changes in the contingent liabilities or contingent assets as at 19 August 2021 from that disclosed in the 2020 Audited Financial Statements.

**A NOTES TO THE INTERIM FINANCIAL REPORT  
FOR THE SECOND QUARTER AND FINANCIAL PERIOD ENDED 30 JUNE 2021**

**A14 CAPITAL COMMITMENTS**

|  | <b>30 Jun 2021</b> | <b>31 Dec 2020</b> |
|--|--------------------|--------------------|
|  | <b>RM'000</b>      | <b>RM'000</b>      |
| <b>a. Capital expenditure commitments</b>                      |                    |                    |
| <i>Property, plant and equipment and investment properties</i> |                    |                    |
| - Contracted but not provided for in the financial statements  | 571,045            | 631,682            |
| <b>b. Other commitments</b>                                    |                    |                    |
| Maximum amount committed for Fortis Open Offer <sup>1</sup>    | 1,879,129          | 1,890,215          |
| Maximum amount committed for Malar Open Offer <sup>1</sup>     | 15,926             | 16,020             |
|  | <u>1,895,055</u>   | <u>1,906,235</u>   |

<sup>1</sup> The actual number of Fortis shares and the actual number of Fortis Malar Hospitals Limited shares that Northern TK Venture Pte. Ltd. ("NTK") will be acquiring can only be determined at the end of the Fortis Open Offer and Malar Open Offer respectively.

On 13 November 2018, IHH acquired 31.17% equity interest in Fortis through a preferential allotment by Fortis to an indirect wholly-owned subsidiary of IHH, NTK. As a consequence of the preferential allotment by Fortis, NTK is required to carry out the following:

- (i) A mandatory open offer for acquisition of up to 197,025,660 equity shares of face value of INR10 each in Fortis, representing additional 26% of the Expanded Voting Share Capital (as defined in Section B6(1)) of Fortis, at a price of not less than INR170 per share ("Fortis Open Offer") or such higher price as required under the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
- (ii) In light of the acquisition of the controlling stake of Fortis, a mandatory open offer for acquisition of up to 4,894,308 fully paid up equity shares of face value of INR10 each in Malar, representing 26% of the paid-up equity shares of Malar at a price of INR58 per share ("Malar Open Offer"). The Malar Open Offer is subject to the completion of the Fortis Open Offer.

In light of the 14 December 2018 status quo Order, and the 15 November 2019 Judgment mentioned in Section B6(1), the Fortis Open Offer as well the Malar Open Offer (which is subject to the completion of the Fortis Open Offer) will not proceed for the time being.

**A NOTES TO THE INTERIM FINANCIAL REPORT  
FOR THE SECOND QUARTER AND FINANCIAL PERIOD ENDED 30 JUNE 2021**

**A15 FAIR VALUE HIERARCHY**

***Fair value hierarchy***

The table below analyses financial instruments carried at fair value. The different levels are defined as follows:

- Level 1: Quoted prices (unadjusted) in active markets for identical assets or liabilities that the Group can access at the measurement date.
- Level 2: Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly.
- Level 3: Unobservable inputs for the asset or liability

|   | Level 1<br>RM'000 | Level 2<br>RM'000 | Level 3<br>RM'000 | Total<br>RM'000 |
|---|-------------------|-------------------|-------------------|-----------------|
| <b><u>30 June 2021</u></b>  |                   |                   |                   |                 |
| <b>Assets</b>   |                   |                   |                   |                 |
| Unquoted shares at FVOCI  | -                 | -                 | 60,378            | 60,378          |
| Money market funds at FVTPL   | -                 | 192,719           | -                 | 192,719         |
| Foreign exchange forward contracts  | -                 | 15,675            | -                 | 15,675          |
| Interest rate caps  | -                 | 2,924             | -                 | 2,924           |
| Cross currency interest rate swaps  | -                 | 17,742            | -                 | 17,742          |
| Cross currency swaps  | -                 | 235,658           | -                 | 235,658         |
|   | -                 | 464,718           | 60,378            | 525,096         |
| <b>Liabilities</b>  |                   |                   |                   |                 |
| Liabilities on put options granted to non-controlling interest <sup>1</sup> | -                 | -                 | (1,255,971)       | (1,255,971)     |
| Interest rate swaps   | -                 | (653)             | -                 | (653)           |
|   | -                 | (653)             | (1,255,971)       | (1,256,624)     |
| <b><u>31 December 2020</u></b>  |                   |                   |                   |                 |
| <b>Assets</b>   |                   |                   |                   |                 |
| Unquoted shares at FVOCI  | -                 | -                 | 59,714            | 59,714          |
| Money market funds at FVTPL   | -                 | 190,915           | -                 | 190,915         |
| Mutual funds at FVTPL   | -                 | 690               | -                 | 690             |
| Foreign exchange forward contracts  | -                 | 6,778             | -                 | 6,778           |
| Interest rate caps  | -                 | 2,704             | -                 | 2,704           |
| Cross currency interest rate swaps  | -                 | 3,883             | -                 | 3,883           |
| Cross currency swaps  | -                 | 128,349           | -                 | 128,349         |
|   | -                 | 333,319           | 59,714            | 393,033         |
| <b>Liabilities</b>  |                   |                   |                   |                 |
| Liabilities on put options granted to non-controlling interest <sup>1</sup> | -                 | -                 | (1,137,658)       | (1,137,658)     |
| Interest rate swaps   | -                 | (886)             | -                 | (886)           |
| Foreign exchange forward contracts  | -                 | (373)             | -                 | (373)           |
| Cross currency interest rate swaps  | -                 | (6,857)           | -                 | (6,857)         |
|   | -                 | (8,116)           | (1,137,658)       | (1,145,774)     |

1. Liabilities on put options granted to non-controlling interests are stated at fair value based on the subsidiary's equity value and the discounted cash flow method based on present value of expected payment discounted using a risk-adjusted discount rate.

Refer to Section B13 for fair value gain/(loss) recognised in the statement of profit or loss.

**A       NOTES TO THE INTERIM FINANCIAL REPORT  
FOR THE SECOND QUARTER AND FINANCIAL PERIOD ENDED 30 JUNE 2021**

**A16     UPDATE ON INVESTIGATIONS BY SECURITIES AND EXCHANGE BOARD OF INDIA (“SEBI”)  
AND SERIOUS FRAUD INVESTIGATION OFFICE (“SFIO”) ON FORTIS**

SEBI issued a show cause notice (“SCN”) dated 20 November 2020 to Fortis and Fortis Hospitals Limited (“FHsL”) in furtherance of the SEBI investigation. In response to the SCN, a joint representation was filed by Fortis and FHsL on 28 December 2020 submitting reasons as to why the SCN ought to be quashed. Oral submissions on the representation have also been completed on 20 January 2021 and written synopsis of the same has been filed. No orders have yet been passed.

SEBI issued another SCN dated 9 April 2021 (“EHIRCL SCN”) to various noticees including Escorts Heart Institute and Research Centre Limited (“EHIRCL”), a subsidiary of Fortis in furtherance of the SEBI investigation. In response thereto, a representation was filed by EHIRCL on 11 June 2021 submitting reasons as to why the EHIRCL SCN ought to be quashed. Oral submissions were also made in a personal hearing before SEBI on 16 June 2021 and a written synopsis of the same has been filed. No orders yet been passed.

As at 19 August 2021, there were no further developments in the ongoing investigation on Fortis by the SFIO, Ministry of Corporate Affairs of India, from that disclosed in Note 46 of the 2020 Audited Financial Statements.

**A17     UPDATE ON THE SUO-MOTO CONTEMPT NOTICE TO FORTIS ON 15TH NOVEMBER 2019**

As at 19 August 2021, there were no further developments in the suo-moto contempt notice to Fortis, from that disclosed in Note 47 of the 2020 Audited Financial Statements. Please refer to section B6(1) for details.

**B ADDITIONAL INFORMATION REQUIRED BY BURSA MALAYSIA'S LISTING REQUIREMENTS FOR THE SECOND QUARTER AND FINANCIAL PERIOD ENDED 30 JUNE 2021**

**B1 REVIEW OF THE PERFORMANCE OF THE COMPANY AND ITS PRINCIPAL SUBSIDIARIES**

|  | 2nd quarter ended |                  |             | Financial period ended |                  |             |
|--|-------------------|------------------|-------------|------------------------|------------------|-------------|
|  | 30 Jun 2021       | 30 Jun 2020      | Variance    | 30 Jun 2021            | 30 Jun 2020      | Variance    |
|  | RM'000            | RM'000           | %           | RM'000                 | RM'000           | %           |
| <b><u>REVENUE</u><sup>1</sup></b>      |                   |                  |             |                        |                  |             |
| Parkway Pantai:                        |                   |                  |             |                        |                  |             |
| - Singapore                            | 1,261,856         | 805,852          | 57%         | 2,417,345              | 1,820,691        | 33%         |
| - Malaysia                             | 662,369           | 434,314          | 53%         | 1,274,287              | 989,747          | 29%         |
| - India                                | 972,714           | 416,609          | 133%        | 1,803,356              | 1,167,185        | 55%         |
| - Greater China                        | 218,867           | 152,959          | 43%         | 406,178                | 281,668          | 44%         |
| - PPL Others*                          | 1,337             | 37,249           | -96%        | 2,844                  | 80,261           | -96%        |
| <b>Parkway Pantai</b>                  | <b>3,117,143</b>  | <b>1,846,983</b> | <b>69%</b>  | <b>5,904,010</b>       | <b>4,339,552</b> | <b>36%</b>  |
| <b>Acibadem Holdings</b>               | <b>1,053,293</b>  | <b>613,858</b>   | <b>72%</b>  | <b>2,113,797</b>       | <b>1,569,635</b> | <b>35%</b>  |
| <b>IMU Health</b>                      | <b>62,237</b>     | <b>63,232</b>    | <b>-2%</b>  | <b>122,056</b>         | <b>130,527</b>   | <b>-6%</b>  |
| <b>Others^</b>                         | <b>645</b>        | <b>1,549</b>     | <b>-58%</b> | <b>1,288</b>           | <b>3,362</b>     | <b>-62%</b> |
| <b>Group (Excluding PLife REIT)</b>    | <b>4,233,318</b>  | <b>2,525,622</b> | <b>68%</b>  | <b>8,141,151</b>       | <b>6,043,076</b> | <b>35%</b>  |
| PLife REIT total revenue               | 91,281            | 92,533           | -1%         | 182,715                | 182,545          | 0%          |
| Less: PLife REIT inter-segment revenue | (54,328)          | (53,045)         | -2%         | (107,815)              | (105,335)        | -2%         |
| <b>PLife REIT</b>                      | <b>36,953</b>     | <b>39,488</b>    | <b>-6%</b>  | <b>74,900</b>          | <b>77,210</b>    | <b>-3%</b>  |
| <b>Group</b>                           | <b>4,270,271</b>  | <b>2,565,110</b> | <b>66%</b>  | <b>8,216,051</b>       | <b>6,120,286</b> | <b>34%</b>  |
| <b><u>EBITDA</u><sup>2</sup></b>       |                   |                  |             |                        |                  |             |
| Parkway Pantai:                        |                   |                  |             |                        |                  |             |
| - Singapore                            | 434,433           | 224,120          | 94%         | 851,893                | 552,351          | 54%         |
| - Malaysia                             | 185,466           | 71,970           | 158%        | 336,132                | 221,580          | 52%         |
| - India                                | 187,875           | (73,451)         | NM          | 304,268                | (4,365)          | NM          |
| - Greater China                        | (13,818)          | (48,810)         | 72%         | (50,080)               | (115,515)        | 57%         |
| - PPL Others*                          | (5,747)           | 4,689            | NM          | (13,451)               | 11,093           | NM          |
| <b>Parkway Pantai</b>                  | <b>788,209</b>    | <b>178,518</b>   | <b>NM</b>   | <b>1,428,762</b>       | <b>665,144</b>   | <b>115%</b> |
| <b>Acibadem Holdings</b>               | <b>300,574</b>    | <b>74,452</b>    | <b>NM</b>   | <b>580,385</b>         | <b>291,712</b>   | <b>99%</b>  |
| <b>IMU Health</b>                      | <b>22,339</b>     | <b>22,800</b>    | <b>-2%</b>  | <b>44,753</b>          | <b>51,276</b>    | <b>-13%</b> |
| <b>Others^</b>                         | <b>(21,237)</b>   | <b>(28,421)</b>  | <b>25%</b>  | <b>(38,699)</b>        | <b>(44,516)</b>  | <b>13%</b>  |
| <b>Group (Excluding PLife REIT)</b>    | <b>1,089,885</b>  | <b>247,349</b>   | <b>NM</b>   | <b>2,015,201</b>       | <b>963,616</b>   | <b>109%</b> |
| <b>PLife REIT</b> <sup>3</sup>         | <b>73,345</b>     | <b>73,274</b>    | <b>0%</b>   | <b>162,394</b>         | <b>143,713</b>   | <b>13%</b>  |
| <b>Eliminations</b> <sup>4</sup>       | <b>(54,578)</b>   | <b>(53,045)</b>  | <b>-3%</b>  | <b>(108,315)</b>       | <b>(105,335)</b> | <b>-3%</b>  |
| <b>Group</b>                           | <b>1,108,652</b>  | <b>267,578</b>   | <b>NM</b>   | <b>2,069,280</b>       | <b>1,001,994</b> | <b>107%</b> |

Note:

<sup>1</sup>: Relates to external revenue only

It excludes PLife REIT's rental income earned from Parkway Pantai

Similarly, it excludes Parkway Pantai's dividend and management fee income earned from PLife REIT

<sup>2</sup>: Relates to the EBITDA performance of each SBUs, after elimination of dividend income from within the Group

<sup>3</sup>: Includes rental income earned from lease of hospitals to Parkway Pantai

<sup>4</sup>: Relates to the elimination of inter-segment income and expenses

\*: PPL Others comprise mainly Parkway Pantai's hospital in Brunei, corporate office as well as other investment holding entities within Parkway Pantai

^: Others comprise mainly IHH Group's corporate office as well as other investment holding entities

**B ADDITIONAL INFORMATION REQUIRED BY BURSA MALAYSIA'S LISTING REQUIREMENTS  
FOR THE SECOND QUARTER AND FINANCIAL PERIOD ENDED 30 JUNE 2021**

**Q2 2021 vs Q2 2020**

The Group's Q2 2021 revenue and EBITDA increased by 66% and 314% over Q2 2020. Q2 2020 was a low base due to major lockdowns in various markets the Group operates in, including Singapore, Malaysia, India and Turkey, as a result of COVID-19 pandemic. During this period, patients postponed non-urgent and non-essential treatments and visits to hospitals and healthcare facilities. Patient volumes picked up as the lockdowns gradually eased to varying extent since June 2020. In addition, the magnitude of COVID-19 related-services provided by the Group also increased as the pandemic continues. The Group was in active collaboration with the public healthcare sector of the countries it operates in since late January 2020 to treat COVID-19 patients, as well as to provide COVID-19 screening, laboratory testing and vaccination services. The consolidation of DDRC SRL since April 2021 and acquisition of PCMC in September 2020 also contributed to the increase in revenue.

The increase in EBITDA was driven by higher revenue, offset by higher staff costs, higher other operating expenses and lower government grant income recorded. The increase in expenses were mainly due to a low base last year with lower doctors' salaries for certain groups of doctors whose salaries vary with revenue or services rendered. The hire of contract employees for COVID-19 related services rendered, as well as the consolidation of DDRC SRL and PCMC also contributed to the higher expenses. Notwithstanding higher expenses, the Group's EBITDA margins improved from 10% in Q2 2020 to 26% in Q2 2021 with the implementation of stringent cost management measures and operational efficiencies from higher patient volumes.

The Group recorded a PATMI excluding exceptional items ("PATMI (Excl EI)") of RM463.6 million in Q2 2021, as compared to RM84.2 million loss for Q2 2020, on the back of stronger EBITDA and higher share of profits from joint ventures and associates. In addition, depreciation and amortisation expenses as well as net finance costs were lower compared to Q2 2020.

***Parkway Pantai***

Parkway Pantai's Q2 2021 revenue increased by 69% to RM3,117.1 million and its Q2 2021 EBITDA increased 341% to RM788.2 million. The higher revenue was mainly due to recovery of patient volumes from a low base in Q2 2020 and a higher contribution from COVID-19 related services rendered.

Parkway Pantai's Singapore hospital inpatient admissions increased by 22% to 15,800 in Q2 2021 while its revenue per inpatient admission increased by 5.7% to RM38,075. Parkway Pantai's Malaysia hospital inpatient admissions increased by 26% to 37,459 in Q2 2021 while its revenue per inpatient admission increased by 18.5% to RM10,323. Parkway Pantai's India hospital inpatient admissions increased by 46% to 69,494 in Q2 2021 while its revenue per inpatient admission increased by 47.8% to RM9,424.

Foreign patient volume remained low since March 2020 as a result of the various travel restrictions implemented across the countries Parkway Pantai operates in.

Parkway Pantai's Q2 2021 EBITDA was driven by higher revenue, offset by higher staff costs from hire of contract staff for COVID-19 related services rendered, higher other operating expenses and lower government grant income recorded. Notwithstanding higher expenses, Parkway Pantai's EBITDA margins improved from 10% in Q2 2020 to 25% in Q2 2021 with the implementation of stringent cost management measures and operational efficiencies from higher patient volumes.

***Acibadem Holdings***

Acibadem Holdings' Q2 2021 revenue increased by 72% to RM1,053.3 million and its EBITDA increased by 304% to RM300.6 million. On a constant currency basis, Acibadem Holdings' Q2 2021 revenue increased 102% while its EBITDA increased 361% over the corresponding period last year. The higher revenue was largely attributed to recovery of patient volumes from a low base in Q2 2020 and price adjustments to counter inflation.

Acibadem Holdings' hospital inpatient admissions increased 49% to 53,375 in Q2 2021. Meanwhile, its revenue per inpatient admission increased 22.1% to RM10,475 with more complex cases undertaken and price adjustments to counter inflation.

Acibadem Holdings' Q2 2021 EBITDA was driven by higher revenue, offset by higher staff costs. Notwithstanding higher expenses, Acibadem Holdings' EBITDA margins improved from 12% in Q2 2020 to 29% in Q2 2021 with

**B ADDITIONAL INFORMATION REQUIRED BY BURSA MALAYSIA'S LISTING REQUIREMENTS  
FOR THE SECOND QUARTER AND FINANCIAL PERIOD ENDED 30 JUNE 2021**

the implementation of stringent cost management measures and operational efficiencies from higher patient volumes.

***IMU Health***

IMU Health's Q2 2021 revenue and EBITDA were slightly lower at RM62.2 million and RM22.3 million respectively. The lower revenue was mainly due to change in academic calendar following the various movement restriction orders as a result the COVID-19 pandemic. Student intake for certain courses also decreased.

IMU Health's lower EBITDA was due to the decrease in revenue, mitigated by lower staff cost and other operating expenses.

***PLife REIT***

PLife REIT's Q2 2021 external revenue decreased 6% to RM37.0 million while its EBITDA was marginally above Q2 2020 at RM73.3 million. The lower revenue resulted from loss of revenue upon divestment of an investment property in Japan in January 2021 and depreciation of Japanese Yen, and was partially compensated by contribution from a nursing home acquired in December 2020. These were more than offset by lower operating expenses.

***Others***

Q2 2021 revenue decreased by 58% to RM0.6 million due to lower dividends received from investments in Money Market Funds ("MMF").

Q2 2021 EBITDA losses decreased by 25% mainly due to a low base last year with IT-related professional fees incurred. In addition, staff cost was lower with the expiry of the LTIP on 24 March 2021.

**YTD 2021 vs YTD 2020**

The Group's YTD 2021 revenue and EBITDA increased by 34% and 107% over YTD 2020. YTD 2020 was a low base due to major lockdowns in various markets the Group operates in, including Singapore, Malaysia, India and Turkey since April 2020 as a result of COVID-19 pandemic. During this period, patients postponed non-urgent and non-essential treatment and visits to hospitals and healthcare facilities. Patient volumes picked up as the lockdowns gradually eased to varying extent since June 2020. In addition, the magnitude of COVID-19 related-services provided by the Group also increased as the pandemic continues. The Group was in active collaboration with the public healthcare sector of the countries it operates in since late January 2020 to treat COVID-19 patients, as well as to provide COVID-19 screening, laboratory testing and vaccination services. The consolidation of DDRC SRL since April 2021 and acquisition of PCMC in September 2020 also contributed to the increase in revenue.

The growth in EBITDA was driven by higher revenue, offset by higher staff costs, higher other operating expenses and lower government grant income. The increase in expenses were mainly due to a low base last year with lower doctors' salaries for certain groups of doctors whose salaries vary with revenue or services rendered. The hire of contract employees for COVID-19 related services rendered, as well as the consolidation of DDRC SRL and PCMC also contributed to the higher expenses. Notwithstanding higher expenses, the Group's EBITDA margins improved from 16% in YTD 2020 to 25% in YTD 2021 with the implementation of stringent cost management measures and operational efficiencies from higher patient volumes.

The Group's YTD 2021 PATMI (Excl EI) increased 660% to RM799.4 million on the back of a higher EBITDA and higher share of profits from joint ventures and associates. In addition, depreciation and amortisation expenses as well as net finance costs were lower compared to YTD 2020.

***Parkway Pantai***

Parkway Pantai's YTD 2021 revenue increased by 36% to RM5,904.0 million and its YTD 2021 EBITDA increased 115% to RM1,428.8 million. The higher revenue was mainly due to recovery of patient volumes from a low base in Q2 2020 and a higher contribution from COVID-19 related services rendered.

**B ADDITIONAL INFORMATION REQUIRED BY BURSA MALAYSIA'S LISTING REQUIREMENTS  
FOR THE SECOND QUARTER AND FINANCIAL PERIOD ENDED 30 JUNE 2021**

Parkway Pantai's Singapore hospital inpatient admissions increased by 8% to 32,582 in YTD 2021 while its revenue per inpatient admission increased 2% to RM36,821. Parkway Pantai's Malaysia hospital inpatient admissions decreased by 9% to 72,403 in YTD 2021 while its revenue per inpatient admission increased by 30.3% to RM10,141. Parkway Pantai's India hospital inpatient admissions increased by 15% to 151,392 in YTD 2021 while its revenue per inpatient admission increased by 30.3% to RM8,263.

Foreign patient volume remained low since March 2020 as a result of the various travel restrictions implemented across the countries Parkway Pantai operates in.

Parkway Pantai's YTD 2021 EBITDA was driven by higher revenue, offset by higher staff costs from hire of contract staff for COVID-19 related services rendered, higher other operating expenses and lower government grant income recorded. Notwithstanding higher expenses, Parkway Pantai's EBITDA margins improved from 15% in YTD 2020 to 24% in YTD 2021 with the implementation of stringent cost management measures and operational efficiencies from higher patient volumes.

***Acibadem Holdings***

Acibadem Holdings' YTD 2021 revenue increased by 35% to RM2,113.8 million and its EBITDA increased by 99% to RM580.4 million. On a constant currency basis, Acibadem Holdings' YTD 2021 revenue increased 58% while its EBITDA increased 137% over the corresponding period last year.

Acibadem Holdings' hospital inpatient admissions increased 19% to 105,016 in YTD 2021. Meanwhile, its revenue per inpatient admission increased 26.5% to RM10,235 with more complex cases undertaken and price adjustments to counter inflation.

Acibadem Holdings' YTD 2021 EBITDA was driven by higher revenue, offset by higher staff costs. Notwithstanding higher expenses, Acibadem Holdings' EBITDA margins improved from 19% in YTD 2020 to 27% in YTD 2021 with the implementation of stringent cost management measures and operational efficiencies from higher patient volumes.

***IMU Health***

IMU Health's YTD 2021 revenue decreased by 6% to RM122.1 million and its YTD 2021 EBITDA decreased by 13% to RM44.8 million. Revenue was affected by the COVID-19 pandemic as IMU Health had to prolong its academic calendar following the various movement restriction orders. Student intake for certain courses also decreased. In addition, YTD 2020 was a higher base with RM3.5 million seminar income from a major conference organised by IMU Health.

IMU Health's lower EBITDA was due to the decrease in revenue.

***PLife REIT***

PLife REIT's YTD 2021 external revenue decreased by 3% to RM74.9 million while its EBITDA increased by 13% to RM162.4 million. The lower revenue resulted from loss of revenue upon divestment of an investment property in Japan in January 2021 and depreciation of Japanese Yen, and was partially compensated by contribution from a nursing home acquired in December 2020. On the other hand, EBITDA was boosted by RM15.7 million gain on divestment of property in January 2021.

***Others***

YTD 2021 revenue decreased by 62% to RM1.3 million due to lower dividends received from investments in MMF. YTD 2021 EBITDA losses decreased by 13% due to a low base last year with IT-related professional fees incurred.

**B ADDITIONAL INFORMATION REQUIRED BY BURSA MALAYSIA'S LISTING REQUIREMENTS FOR THE SECOND QUARTER AND FINANCIAL PERIOD ENDED 30 JUNE 2021**

**B2 MATERIAL CHANGE IN QUARTERLY RESULTS**

|  | 2nd quarter ended<br>30 Jun 2021<br>RM'000 | 1st quarter ended<br>31 Mar 2021<br>RM'000 | Variance<br>% |
|--|--|--|---------------|
| <b><u>REVENUE</u><sup>1</sup></b>      |  |  |               |
| Parkway Pantai:                        |  |  |               |
| - Singapore                            | 1,261,856                                  | 1,155,489                                  | 9%            |
| - Malaysia                             | 662,369                                    | 611,918                                    | 8%            |
| - India                                | 972,714                                    | 830,642                                    | 17%           |
| - Greater China                        | 218,867                                    | 187,311                                    | 17%           |
| - PPL Others*                          | 1,337                                      | 1,507                                      | -11%          |
| <b>Parkway Pantai</b>                  | <b>3,117,143</b>                           | <b>2,786,867</b>                           | <b>12%</b>    |
| <b>Acibadem Holdings</b>               | <b>1,053,293</b>                           | <b>1,060,504</b>                           | <b>-1%</b>    |
| <b>IMU Health</b>                      | <b>62,237</b>                              | <b>59,819</b>                              | <b>4%</b>     |
| <b>Others<sup>^</sup></b>              | <b>645</b>                                 | <b>643</b>                                 | <b>0%</b>     |
| <b>Group (Excluding PLife REIT)</b>    | <b>4,233,318</b>                           | <b>3,907,833</b>                           | <b>8%</b>     |
| PLife REIT total revenue               | 91,281                                     | 91,434                                     | 0%            |
| Less: PLife REIT inter-segment revenue | (54,328)                                   | (53,487)                                   | -2%           |
| <b>PLife REIT</b>                      | <b>36,953</b>                              | <b>37,947</b>                              | <b>-3%</b>    |
| <b>Group</b>                           | <b>4,270,271</b>                           | <b>3,945,780</b>                           | <b>8%</b>     |
| <b><u>EBITDA</u><sup>2</sup></b>       |  |  |               |
| Parkway Pantai:                        |  |  |               |
| - Singapore                            | 434,433                                    | 417,460                                    | 4%            |
| - Malaysia                             | 185,466                                    | 150,666                                    | 23%           |
| - India                                | 187,875                                    | 116,393                                    | 61%           |
| - Greater China                        | (13,818)                                   | (36,262)                                   | 62%           |
| - PPL Others*                          | (5,747)                                    | (7,704)                                    | 25%           |
| <b>Parkway Pantai</b>                  | <b>788,209</b>                             | <b>640,553</b>                             | <b>23%</b>    |
| <b>Acibadem Holdings</b>               | <b>300,574</b>                             | <b>279,811</b>                             | <b>7%</b>     |
| <b>IMU Health</b>                      | <b>22,339</b>                              | <b>22,414</b>                              | <b>0%</b>     |
| <b>Others<sup>^</sup></b>              | <b>(21,237)</b>                            | <b>(17,462)</b>                            | <b>-22%</b>   |
| <b>Group (Excluding PLife REIT)</b>    | <b>1,089,885</b>                           | <b>925,316</b>                             | <b>18%</b>    |
| <b>PLife REIT<sup>3</sup></b>          | <b>73,345</b>                              | <b>89,049</b>                              | <b>-18%</b>   |
| <b>Eliminations<sup>4</sup></b>        | <b>(54,578)</b>                            | <b>(53,737)</b>                            | <b>-2%</b>    |
| <b>Group</b>                           | <b>1,108,652</b>                           | <b>960,628</b>                             | <b>15%</b>    |

Note:

<sup>1</sup>: Relates to external revenue only

It excludes PLife REIT's rental income earned from Parkway Pantai

Similarly, it excludes Parkway Pantai's dividend and management fee income earned from PLife REIT

<sup>2</sup>: Relates to the EBITDA performance of each SBUs, after elimination of dividend income from within the Group

<sup>3</sup>: Includes rental income earned from lease of hospitals to Parkway Pantai

<sup>4</sup>: Relates to the elimination of inter-segment income and expenses

\*: PPL Others comprise mainly Parkway Pantai's hospital in Brunei, corporate office as well as other investment holding entities within Parkway Pantai

<sup>^</sup>: Others comprise mainly IHH Group's corporate office as well as other investment holding entities

**B ADDITIONAL INFORMATION REQUIRED BY BURSA MALAYSIA'S LISTING REQUIREMENTS  
FOR THE SECOND QUARTER AND FINANCIAL PERIOD ENDED 30 JUNE 2021**

**Q2 2021 vs Q1 2021**

The Group reported an 8% quarter-on-quarter increase in revenue and a 15% quarter-on-quarter increase in EBITDA. The growth in revenue was mainly from COVID-19 related services rendered, which increased in both volume and scope. EBITDA increased 15% quarter-on-quarter despite a higher base in Q1 2021 whereby a RM15.6 million gain on divestment of investment property was recorded.

The Group's PATMI (Excl EI) increased 38% quarter-on-quarter with a higher EBITDA and lower net finance cost in Q2 2021 mainly due to lower loan quantum in Q2 2021. These are partially offset by lower share of profits of joint ventures with consolidation of DDRC SRL since April 2021.

***Parkway Pantai***

Parkway Pantai's revenue increased 12% quarter-on-quarter while its EBITDA increased 23% quarter-on-quarter. The growth in revenue was largely attributed to COVID-19 related services rendered.

Parkway Pantai's Singapore hospital inpatient admissions decreased 6% quarter-on-quarter, while its revenue per inpatient admission increased 6.8%. Parkway Pantai's Malaysia hospitals inpatient admissions increased 7% quarter-on-quarter, while its revenue per inpatient admission increased 3.8%. Parkway Pantai's India hospitals inpatient admissions decreased 15% quarter-on-quarter, while its revenue per inpatient admission increased 29.5%.

EBITDA grew quarter-on-quarter on the back of a stronger revenue.

***Acibadem Holdings***

Acibadem Holdings' revenue was marginally lower quarter-on-quarter while its EBITDA increased 7% quarter-on-quarter. On a constant currency basis, Acibadem Holdings' revenue increased 8% quarter-on-quarter while its EBITDA increased 17% quarter-on-quarter.

Acibadem Holdings' inpatient admissions increased 3% quarter-on-quarter while its revenue per inpatient increased 4.9% quarter-on-quarter.

***IMU Health***

IMU Health's revenue increased 4% quarter-on-quarter mainly due to change in academic calendar.

EBITDA was flat quarter-on-quarter despite an increase in revenue due to higher expenses in Q2 2021 as a result of increased activities.

***PLife REIT***

PLife REIT's Q2 2021 external revenue was 3% lower than Q1 2021 due to loss of revenue upon divestment of an investment property in Japan in January 2021.

Q1 2021 EBITDA was a high base with RM15.6 million gain on divestment of investment property recorded. Excluding the divestment gain, PLife REIT's Q2 2021 EBITDA was flat against Q1 2021.

***Others***

Revenue was flat against Q1 2021 while EBITDA losses increased 22% quarter-on-quarter due to higher staff costs.

**B ADDITIONAL INFORMATION REQUIRED BY BURSA MALAYSIA'S LISTING REQUIREMENTS  
FOR THE SECOND QUARTER AND FINANCIAL PERIOD ENDED 30 JUNE 2021**

**B3 CURRENT YEAR FINANCIAL PROSPECTS**

The COVID-19 pandemic has presented unprecedented challenges to the global economy, across all industries including healthcare. The Group is adapting to the new normal and repositioning itself for growth amidst this pandemic.

Although patient volume is impacted by the resurgence of COVID-19 cases across the globe and by the various movement restrictions implemented, the Group's diversified earnings provides it with the resilience to weather the pandemic as its key markets recover from the varying extents of the pandemic. The Group will accelerate efforts to drive patient volumes and diversify into new revenue streams. The Group is in active collaboration with the public healthcare sector to provide COVID-19 screening services, treating COVID-19 patients and perform COVID-19 laboratory testing. In support of mass vaccination efforts around the world, our teams in Malaysia, Singapore, India, Turkey, and Hong Kong have stepped up to assist the governments and public sector in administering COVID-19 vaccine to its residents. COVID-19 related services contributed about between 12% - 31% of the Q2 2021 revenues from the Group's operations in its home markets.

Given the nature of hospital operations, some costs, such as staff costs and depreciation, remains relatively fixed despite lower patient volumes. The Group continually maintains a tight rein on costs and has strict cash management, which includes deferment of non-critical purchases and non-critical capital expansion projects.

The Group is confident that its longer-term growth trajectory remains intact. It remains disciplined in delivering its Refreshed Strategy, which is centered on becoming the world's most trusted healthcare services provider, even as it stays nimble in adapting to the pandemic. COVID-19 has accelerated the push towards greater adoption of digitalisation and technology to boost productivity. The Group has aligned its efforts to innovate and deliver healthcare digitally, such as introducing telemedicine. With an international network of hospitals, the Group seeks to extract greater synergies by leveraging economies of scale to achieve lower costs and better optimisation of resources.

The Group continues to deepen its metro cluster strategy to drive efficient growth by constantly reviewing and calibrating its asset portfolio. The acquisition of the Serbian-based Bel Medic Group by Acibadem has been completed in July 2021 and would start contributing to the Group's revenue.

As the Group transits to a post-pandemic world, it is cautiously optimistic of a progressive recovery driven by long term mega trends despite short-term headwinds. Although the Group expects continued impact from the COVID-19 pandemic for the rest of this year, it believes it is well-prepared to ride out this pandemic and emerge stronger. The Group remains guided by its vision and anchored by trust with all stakeholders.

**B ADDITIONAL INFORMATION REQUIRED BY BURSA MALAYSIA'S LISTING REQUIREMENTS FOR THE SECOND QUARTER AND FINANCIAL PERIOD ENDED 30 JUNE 2021**

**B4 PROFIT FORECAST/GUARANTEE**

Not applicable as no profit forecast/guarantee was issued.

**B5 TAXATION**

|                      | 2nd quarter ended |             | Financial period ended |             |
|----------------------|-------------------|-------------|------------------------|-------------|
|                      | 30 Jun 2021       | 30 Jun 2020 | 30 Jun 2021            | 30 Jun 2020 |
|                      | RM'000            | RM'000      | RM'000                 | RM'000      |
| Current tax expense  | 143,828           | 60,097      | 246,506                | 139,798     |
| Deferred tax expense | (21,449)          | (59,983)    | 29,483                 | (30,381)    |
|                      | 122,379           | 114         | 275,989                | 109,417     |

QTD 2021 and YTD 2021 effective tax rate\* were 18.6% and 22.5% respectively and were lower than the Malaysia statutory tax rate due to certain non-tax deductible income and expenses (refer to page 2 for list of exceptional items).

QTD 2020 and YTD 2020 effective tax rate\* were 0.0% and -22.4% respectively, mainly due to certain non-tax deductible expenses (refer to page 2 for list of exceptional items), unrecognised tax losses arising from the subsidiaries' operations, and hospitals under construction. In addition, most of the COVID-19-related government grants recognised by the Group are not taxable.

\* Effective tax rate, after adjusting for the Group's share of profits of associates and joint ventures

**B6 STATUS OF CORPORATE PROPOSALS**

Save as disclosed below, there were no other corporate proposals announced but not completed as at 19 August 2021:

1. Proposed subscription of 235,294,117 new equity shares of face value of Indian Rupee ("INR") 10 each ("Fortis Shares") in Fortis Healthcare Limited ("Fortis") through preferential allotment by Fortis to an indirect wholly-owned subsidiary of IHH, Northern TK Venture Pte Ltd ("NTK" or the "Acquirer") ("Proposed Subscription");

Mandatory Open Offer for acquisition of up to 197,025,660 Fortis Shares representing additional 26% of the Expanded Voting Share Capital (as defined herein) of Fortis by the Acquirer ("Fortis Open Offer"); and

Mandatory Open Offer for acquisition of up to 4,894,308 fully paid up equity shares of face value of INR10 each, representing 26% of the fully diluted voting equity share capital of Fortis Malar Hospitals Limited ("Malar") by the Acquirer ("Malar Open Offer").

On 13 July 2018, pursuant to a board resolution passed by the Board of Directors of Fortis, NTK, as subscriber, entered into a share subscription agreement ("Fortis SSA") with Fortis, as issuer, where NTK has agreed to subscribe 235,294,117 new equity shares of Fortis with a face value of INR10 each ("Subscription Shares"), constituting approximately 31.17% of the total voting equity share capital of Fortis on a fully diluted basis ("Expanded Voting Share Capital") for a total consideration of INR4,000 crore and Fortis has agreed to issue and allot the Subscription Shares by way of preferential allotment in accordance with the terms of the Fortis SSA ("Proposed Subscription"). The Proposed Subscription was completed in accordance with the terms of the Fortis SSA on 13 November 2018 and NTK has become the controlling shareholder of Fortis.

As a consequence of the Proposed Subscription, NTK was required to carry out the following:

- (i) A mandatory open offer for acquisition of up to 197,025,660 equity shares of face value of INR10 each in Fortis, representing additional 26% of the Expanded Voting Share Capital of Fortis, at a price of not less than INR170 per share ("Fortis Open Offer") or such higher price as required under the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 ("SEBI (SAST) Regulations").

**B ADDITIONAL INFORMATION REQUIRED BY BURSA MALAYSIA'S LISTING REQUIREMENTS  
FOR THE SECOND QUARTER AND FINANCIAL PERIOD ENDED 30 JUNE 2021**

On 13 July 2018, NTK, together with IHH and Parkway Pantai Limited, in the capacity as the persons acting in concert with NTK (collectively, the "PACs"), pursuant to the terms of Regulations 3(1) and 4 read with Regulation 15(1) of the SEBI (SAST) Regulations, have made the Fortis Open Offer by filing of the public announcement dated 13 July 2018 ("Fortis Public Announcement") to all the shareholders of Fortis who are eligible to tender their shares in the Fortis Open Offer, excluding NTK and the PACs and persons deemed to be acting in concert with NTK and the PACs. Save and except for the PACs, no other person is acting in concert with NTK for the purpose of the Fortis Open Offer at the time of the Fortis Public Announcement being released.

- (ii) In light of the acquisition of the controlling stake of Fortis, a mandatory open offer for acquisition of up to 4,894,308 fully paid up equity shares of face value of INR10 each in Malar, representing 26% of the paid-up equity shares of Malar at a price of INR58 per share ("Malar Open Offer"). The Malar Open Offer is subject to the completion of the Fortis Open Offer.

On 13 July 2018, NTK together with the PACs pursuant to the terms of Regulations 3(1), 4 and 5(1) read with Regulations 13(2)(e) and 15(1) of the SEBI (SAST) Regulations, have made the Malar Open Offer by filing of the public announcement dated 13 July 2018 ("Malar Public Announcement") to all the public shareholders of Malar excluding the promoter and promoter group of Malar, NTK and the PACs and persons deemed to be acting in concert with NTK and the PACs. Save and except for the PACs, no other person is acting in concert with NTK for the purpose of the Malar Open Offer at the time of the Malar Public Announcement being released.

On 14 December 2018, the Supreme Court of India passed an order in the matter of "Mr Vinay Prakash Singh v. Sameer Gehlaut & Ors.", directing "status quo with regard to sale of the controlling stake in Fortis to Malaysian IHH Healthcare Berhad be maintained" ("Order"). Pursuant thereto, decision was taken not to proceed with Open Offer.

Vide its judgment dated 15 November 2019 ("Judgment"), the Supreme Court of India issued suo-moto contempt notice to, among others, Fortis, and directed its Registry to register a fresh contempt petition in regard to alleged violation of the Order. In this respect, the Supreme Court sought an enquiry into:

- (i) Whether the subscription by NTK for the Shares of Fortis was undertaken after the Order, and accordingly if such subscription was in violation of the Order; and
- (ii) The consummation of the acquisition of healthcare assets from RHT Health Trust by Fortis.

Fortis has filed a reply to the show cause notice issued in the suo-moto contempt, praying inter alia, that the suo-moto contempt proceedings be dropped and Order be modified/vacated such that the open offers may proceed.

Since the issuance of the Judgment, several parties have, inter alia, filed applications before the Supreme Court, for seeking various remedies, which are briefly enumerated below (where relevant to IHH or Fortis):

- a) Anshuman Khanna, a minority shareholder of Fortis ("Minority Shareholder") has sought resumption of the Fortis Open Offer but has asked that IHH to pay interest at 10% (ten percent) to the public shareholders of Fortis who are eligible to tender shares in the Fortis Open Offer due to the delay since IHH is earning interest on the 100% of the consideration payable under the Fortis Open Offer that has deposited in the escrow account.
- b) Daiichi Sankyo Co. Ltd ("Daiichi") has sought permission to implead itself in and present its case stating that its rights are impacted by orders that may be passed in the Fortis Contempt Petition.
- c) SEBI has sought resumption of the Fortis Open Offer citing larger public interest at stake.
- d) On 5 March 2020, NTK has through its legal counsel, filed applications to intervene in the aforementioned Supreme Court Proceedings, as follows:
- (i) intervention applications in the Original Contempt Petition and the Fortis Contempt Petition, respectively, and to enable NTK to be heard in the Supreme Court Proceedings before any further orders are passed by the Supreme Court; and

**B ADDITIONAL INFORMATION REQUIRED BY BURSA MALAYSIA’S LISTING REQUIREMENTS  
FOR THE SECOND QUARTER AND FINANCIAL PERIOD ENDED 30 JUNE 2021**

- (ii) an application to vacate the Order that continues to stay the Fortis Open Offer so as to be able to consummate the Fortis Open Offer; and support SEBI’s ask of resuming the same.

Further, NTK may file such other applications, replies and affidavits, as necessary, to respond to the applications filed by any other parties.

- e) On 14 August 2020 Fortis has submitted an application to the Supreme Court of India seeking approval to undertake a change in the company name, brand and logo for Fortis and its subsidiaries (“Fortis Rebranding Application”).

The Fortis Contempt Petition, the Order, the Original Contempt Petition, the applications filed by the Minority Shareholder, Daiichi and SEBI, and the Fortis Rebranding Application, respectively, are collectively referred to as “Supreme Court Proceedings”.

Fortis has filed an additional affidavit responding to the queries put forth by Supreme Court. Arguments are being heard by the Supreme Court of India for adjudication of the matters pending before it.

Hearings in the Supreme Court Proceedings have concluded on 12 May 2021 and the judgement is now reserved. Outcome of the Supreme Court Proceedings cannot be predicted at this juncture and the potential liability to IHH is indeterminate, at this stage.

**B ADDITIONAL INFORMATION REQUIRED BY BURSA MALAYSIA'S LISTING REQUIREMENTS  
FOR THE SECOND QUARTER AND FINANCIAL PERIOD ENDED 30 JUNE 2021**

**B7 LOANS, BORROWINGS AND OVERDRAFTS**

(a) Breakdown of the Group's loans, borrowings and overdrafts:

|                              | <b>30 Jun 2021</b>      | <b>31 Dec 2020</b>      |
|------------------------------|-------------------------|-------------------------|
|                              | <b>RM'000</b>           | <b>RM'000</b>           |
| <b>Non-current</b>           |                         |                         |
| Secured                      |                         |                         |
| Bank loans                   | 1,072,960               | 1,091,363               |
| Loans from corporates        | 2,198                   | 2,296                   |
| Unsecured                    |                         |                         |
| Bank loans                   | 5,528,821               | 6,183,745               |
| Fixed rate medium term notes | 443,445                 | 462,925                 |
| Loans from corporates*       | 923,747                 | 924,347                 |
|                              | <u>7,971,171</u>        | <u>8,664,676</u>        |
| <b>Current</b>               |                         |                         |
| Secured                      |                         |                         |
| Bank overdrafts              | 37,322                  | 22,401                  |
| Bank loans                   | 348,531                 | 336,204                 |
| Loans from corporates        | 827                     | 988                     |
| Unsecured                    |                         |                         |
| Bank loans                   | 648,865                 | 658,534                 |
| Loans from corporates        | 666                     | 658                     |
|                              | <u>1,036,211</u>        | <u>1,018,785</u>        |
| <b>Total</b>                 | <u><b>9,007,382</b></u> | <u><b>9,683,461</b></u> |

\* Includes loans from non-controlling interests of RM861,369,000 (2020: RM863,921,000)

Breakdown of the Group's loans, borrowings and overdrafts by the source currency of loans, in RM equivalent:

|                  | <b>30 Jun 2021</b> | <b>31 Dec 2020</b> |
|------------------|--------------------|--------------------|
|                  | <b>RM'000</b>      | <b>RM'000</b>      |
| Singapore Dollar | 1,965,712          | 2,711,869          |
| Hong Kong Dollar | 2,653,212          | 2,584,177          |
| Japanese Yen     | 1,796,956          | 1,786,607          |
| Euro             | 1,195,982          | 1,244,247          |
| Indian Rupees    | 955,332            | 1,015,116          |
| Renminbi         | 398,479            | 310,301            |
| Macedonian Denar | 9,669              | 16,182             |
| Ringgit Malaysia | 30,740             | 13,677             |
| Others           | 1,300              | 1,285              |
|                  | <u>9,007,382</u>   | <u>9,683,461</u>   |

**B ADDITIONAL INFORMATION REQUIRED BY BURSA MALAYSIA'S LISTING REQUIREMENTS  
FOR THE SECOND QUARTER AND FINANCIAL PERIOD ENDED 30 JUNE 2021**

**B8 FINANCIAL DERIVATIVE INSTRUMENTS**

The Group's outstanding net derivative financial instruments as at 30 June 2021:

|  | <b>Notional<br/>amount as at<br/>30 Jun 2021<br/>RM'000</b> | <b>Fair value<br/>amount as at<br/>30 Jun 2021<br/>RM'000</b> |
|--|---|---|
| <b>Derivative assets</b>                         |   |   |
| Foreign exchange forward contracts               |   |   |
| - Within 1 year                                  | 52,845  | 3,472   |
| - Between 1 - 3 years                            | 86,838  | 6,877   |
| - More than 3 years                              | 71,055  | 5,326   |
|  | <u>210,738</u>  | <u>15,675</u>   |
| Interest rate caps                               |   |   |
| - More than 3 years                              | 886,807   | 2,924   |
| Cross currency interest rate swaps               |   |   |
| - More than 3 years                              | 253,640   | 17,742  |
| Cross currency swaps                             |   |   |
| - Within 1 year                                  | 178,266   | 67,151  |
| - Between 1 - 3 years                            | 357,326   | 134,617   |
| - More than 3 years                              | 89,928  | 33,890  |
|  | <u>625,520</u>  | <u>235,658</u>  |
|  | <u>1,976,705</u>  | <u>271,999</u>  |
| <b>Derivative liabilities</b>                    |   |   |
| Interest rate swaps                              |   |   |
| - Within 1 year                                  | 139,828   | (17)  |
| - Between 1 - 3 years                            | 165,477   | (636)   |
|  | <u>305,305</u>  | <u>(653)</u>  |
| Call option granted to non-controlling interests |   |   |
| - Within 1 year                                  | 28,051  | -   |
|  | <u>333,356</u>  | <u>(653)</u>  |

***Foreign exchange forward contracts***

Foreign exchange forward contracts are entered by the Group to hedge against exchange rate exposures on some balances denominated in currencies other than the functional currency of the entity that recognised the foreign currency balances. The fair value of foreign exchange forward contract is determined based on prevailing market rate.

***Interest rate caps***

Interest rate caps are entered by the Group to protect against an increase in interest rates beyond the pre-determined cap rate.

**B ADDITIONAL INFORMATION REQUIRED BY BURSA MALAYSIA'S LISTING REQUIREMENTS  
FOR THE SECOND QUARTER AND FINANCIAL PERIOD ENDED 30 JUNE 2021**

***Cross currency interest rate swaps and cross currency swaps***

Cross currency interest rate swaps and cross currency swaps are entered by the Group to hedge the interest rate fluctuations on the floating rate borrowings, and to realign certain borrowings to the same currency of the Group's foreign investments to achieve a natural hedge. The fair values of cross currency interest rate swaps and cross currency swaps are determined based on bank quotes.

***Interest rate swaps***

Interest rate swaps are entered by the Group to hedge against interest rate fluctuations on some floating rate borrowings. The fair value of interest rate swaps is determined based on bank quotes.

***Call option granted to non-controlling interests***

Call option granted to non-controlling interests relates to a call option granted by the Group to non-controlling interests of Ravindranath GE Medical Associates Pte Ltd ("RGE") to purchase the Group's 3% interest in RGE on a fully diluted basis at a fixed price of INR500.0 million, pursuant to an option agreement entered with the non-controlling interests. The call option granted to non-controlling interests is classified as a derivative liability.

There are no changes to the Group's financial risk management policies and objectives in managing these derivative financial instruments and its related accounting policies. Refer to Section B13 for the fair value gain/loss recognised in the statement of profit or loss.

**B9 FAIR VALUE CHANGES OF FINANCIAL LIABILITIES**

Other than as disclosed in Section A15 the Group does not remeasure its financial liabilities and derivatives at reporting date. The changes in fair value recognised through profit or loss are disclosed in Section B13.

**B10 MATERIAL LITIGATIONS**

Except as mentioned in Section A13, there were no other material changes in the contingent material litigations as at 19 August 2021 from that disclosed in the 2020 Audited Financial Statements.

**B11 DIVIDENDS**

No dividends were declared or paid by the Company during the financial period ended 30 June 2021.

For details of the dividends paid by the Company during the quarter ended 30 June 2021, please refer to Section A7.

**B ADDITIONAL INFORMATION REQUIRED BY BURSA MALAYSIA'S LISTING REQUIREMENTS FOR THE SECOND QUARTER AND FINANCIAL PERIOD ENDED 30 JUNE 2021**

**B12 EARNINGS PER SHARE ("EPS")**

Basic earnings per share were calculated by dividing the Group's net profit attributable to shareholders less distribution to holders of the perpetual securities, by the weighted average number of ordinary shares in issue during the financial period.

|  | 2nd quarter ended |                  | Financial period ended |                  |
|--|-------------------|------------------|------------------------|------------------|
|  | 30 Jun 2021       | 30 Jun 2020      | 30 Jun 2021            | 30 Jun 2020      |
|  | RM'000            | RM'000           | RM'000                 | RM'000           |
| Basic and diluted earnings per share is based on:  |                   |                  |                        |                  |
| i) <u>Net profit attributable to ordinary shareholders</u>   |                   |                  |                        |                  |
| Profit/(Loss) after tax and non-controlling interests  | 483,306           | (120,642)        | 858,927                | (440,428)        |
| Perpetual securities distribution accrued  | (21,917)          | (22,974)         | (43,285)               | (45,314)         |
|  | <u>461,389</u>    | <u>(143,616)</u> | <u>815,642</u>         | <u>(485,742)</u> |
| ii) <u>Net profit attributable to ordinary shareholders (excluding EI)</u>   |                   |                  |                        |                  |
| Profit/(Loss) after tax and non-controlling interests (excluding EI)   | 463,584           | (84,155)         | 799,410                | 105,196          |
| Perpetual securities distribution accrued  | (21,917)          | (22,974)         | (43,285)               | (45,314)         |
|  | <u>441,667</u>    | <u>(107,129)</u> | <u>756,125</u>         | <u>59,882</u>    |
| <b>(a) Basic EPS</b>   |                   |                  |                        |                  |
|  | '000              | '000             | '000                   | '000             |
| Weighted average number of shares  | <u>8,779,073</u>  | <u>8,775,344</u> | <u>8,778,367</u>       | <u>8,774,667</u> |
|  | sen               | sen              | sen                    | sen              |
| Basic EPS  | 5.26              | (1.64)           | 9.29                   | (5.54)           |
| Basic EPS (excluding EI)   | <u>5.03</u>       | <u>(1.22)</u>    | <u>8.61</u>            | <u>0.68</u>      |
| <b>(b) Diluted earnings per share</b>  |                   |                  |                        |                  |
| For diluted EPS, the weighted average number of ordinary shares in issue is adjusted to assume conversion of all potentially dilutive ordinary shares. |                   |                  |                        |                  |
|  | 2nd quarter ended |                  | Financial period ended |                  |
|  | 30 Jun 2021       | 30 Jun 2020      | 30 Jun 2021            | 30 Jun 2020      |
|  | '000              | '000             | '000                   | '000             |
| Weighted average number of ordinary shares used in calculation of basic earnings per share   | 8,779,073         | 8,775,344        | 8,778,367              | 8,774,667        |
| Weighted number of unissued ordinary shares from units under Long Term Incentive Plan  | -                 | 3,014            | 925                    | 3,184            |
| Weighted average number of dilutive ordinary shares for computation of diluted EPS   | <u>8,779,073</u>  | <u>8,778,358</u> | <u>8,779,292</u>       | <u>8,777,851</u> |
|  | sen               | sen              | sen                    | sen              |
| Diluted EPS  | 5.26              | (1.64)           | 9.29                   | (5.53)           |
| Diluted EPS (excluding EI)   | <u>5.03</u>       | <u>(1.22)</u>    | <u>8.61</u>            | <u>0.68</u>      |

At 30 June 2021, 45,590,000 outstanding EOS options (30 June 2020: 50,254,000) were excluded from the diluted weighted average number of ordinary shares calculation as their effect would have been anti-dilutive.

**B ADDITIONAL INFORMATION REQUIRED BY BURSA MALAYSIA'S LISTING REQUIREMENTS FOR THE SECOND QUARTER AND FINANCIAL PERIOD ENDED 30 JUNE 2021**

**B13 NOTES TO THE STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME**

|   | 2nd quarter ended |             | Financial period ended |             |
|---|-------------------|-------------|------------------------|-------------|
|   | 30 Jun 2021       | 30 Jun 2020 | 30 Jun 2021            | 30 Jun 2020 |
|   | RM'000            | RM'000      | RM'000                 | RM'000      |
| Dividend income   | 645               | 1,549       | 1,288                  | 3,362       |
| Other operating income  | 78,606            | 154,253     | 151,528                | 236,420     |
| Foreign exchange differences  | 799               | 3,185       | 4,527                  | 15,274      |
| Impairment loss (made)/written back:                                |                   |             |                        |             |
| - Goodwill  | -                 | 1,330       | -                      | (399,153)   |
| - Trade and other receivables                                       | (46,273)          | (28,360)    | (61,450)               | (41,484)    |
| - Inventories   | (224)             | (335)       | 159                    | (436)       |
| Write off:  |                   |             |                        |             |
| - Property, plant and equipment                                     | (862)             | (709)       | (916)                  | (896)       |
| - Trade and other receivables                                       | (5,916)           | (1,494)     | (6,564)                | (3,418)     |
| - Inventories   | (1,184)           | (880)       | (1,804)                | (1,541)     |
| Remeasurement to fair value of interest in a joint venture          | 85,768            | -           | 85,768                 | -           |
| (Loss)/Gain on disposal of property, plant and equipment            | (38)              | 5,251       | 1,489                  | 4,807       |
| Gain on divestment of an investment property                        | 118               | -           | 15,722                 | -           |
| Gain on disposal of a subsidiary                                    | -                 | -           | -                      | 13,188      |
| Gain on disposal of a joint venture                                 | 139,053           | -           | 139,053                | -           |
| Realisation of FCTR upon substantive liquidation of a joint venture | -                 | (434)       | -                      | (60,419)    |
| Provision for loan taken by a joint venture                         | -                 | (1,279)     | -                      | (2,441)     |
| Finance income  |                   |             |                        |             |
| Interest income   | 14,543            | 12,672      | 24,329                 | 29,607      |
| Fair value (loss)/gain on financial instruments                     | (1,504)           | 45,512      | 164,620                | 101,309     |
|   | 13,039            | 58,184      | 188,949                | 130,916     |
| Finance costs   |                   |             |                        |             |
| Interest on loans and borrowings                                    | (66,715)          | (80,967)    | (162,453)              | (166,767)   |
| Interest on lease liabilities                                       | (39,381)          | (41,007)    | (79,855)               | (84,300)    |
| Exchange loss on net borrowings                                     | (58,724)          | (94,826)    | (157,928)              | (228,652)   |
| Fair value (loss)/gain on financial instruments                     | (252)             | 6,650       | -                      | (8,610)     |
| Other finance costs   | (7,643)           | (7,206)     | (16,698)               | (17,661)    |
|   | (172,715)         | (217,356)   | (416,934)              | (505,990)   |